Methods and compositions for increasing expression of UBE3a

By degrading the UBE3A-ATS transcript in cells of the central nervous system using complementary RNAs, the method increases UBE3A expression, addressing the genetic deficiency underlying Angelman syndrome and offering a potential therapeutic avenue.

WO2025101533A1PCT designated stage expired Publication Date: 2025-05-15ENCODED THERAPEUTICS INC

Patent Information

Application Number
PCT/US2024/054601
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-11-09
Filing Date
2024-11-05
Publication Date
2025-05-15

AI Technical Summary

Technical Problem

Angelman syndrome, caused by deletion or mutation of the UBE3A gene, results in severe intellectual disability, developmental delay, and seizures, with no current cure available.

Method used

The method involves targeting the UBE3A-ATS transcript for degradation in cells of the central nervous system using nucleic acid cassettes that encode RNAs complementary to regions of UBE3A-ATS, thereby activating the paternal UBE3A allele and increasing UBE3A expression.

Benefits of technology

This approach effectively increases UBE3A expression in cells, potentially mitigating the symptoms of Angelman syndrome by enhancing gene function in the central nervous system.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2024054601_15052025_PF_FP_ABST
    Figure US2024054601_15052025_PF_FP_ABST
Patent Text Reader

Abstract

This disclosure provides, among other things, methods and compositions for increasing UBE3A expression in cells, particularly cells that express UBE3A-ATS. In some embodiments, this disclosure provides nucleic acid cassettes that encode RNAs that are complementary to one or more regions of UBE3A-ATS. In some embodiments, the disclosure provides a nucleic acid cassette comprising a transgene encoding an RNA that binds a nucleotide sequence between positions 25,170,426 and 25,252,333 on human chromosome 15.
Need to check novelty before this filing date? Find Prior Art

Description

METHODS AND COMPOSITIONS FOR INCREASING EXPRESSION OF UBE3ACROSS-REFERENCING

[0001] This application claims the benefit of U.S. provisional application serial no. 63 / 597,669, filed on November 9, 2023, which application is incorporated by reference for all purposes.INCORPORATION BY REFERENCE OF SEQUENCE LISTING PROVIDED AS A SEQUENCE LISTING XML

[0002] A Sequence Listing is provided herewith as a Sequence Listing XML, “ENCO- 008WO_SEQ_LIST”, created on November 5, 2024, and having a size of 155,238 bytes. The contents of the Sequence Listing XML are incorporated herein by reference in their entirety.BACKGROUND

[0003] Angclman syndrome is a genetic disorder that affects between 1 in 12,000 to 1 in 20,000 people. Symptoms are generally apparent by one year of age, and include severe intellectual disability, developmental delay and seizures. Generally, Angelman syndrome is caused by deletion or mutation of the UBE3A gene. UBE3A is subject to genomic imprinting, a naturally occurring phenomenon that may silence one allele of a gene while leaving the other allele on. In neurons of the central nervous system (CNS), the paternal UBE3A allele is generally off, whereas in other cell types of the body, both alleles of UBE3A are generally on. Angelman syndrome is generally associated with deletion or mutation of the maternal UBE3A gene. There is currently no cure available.SUMMARY

[0004] This disclosure provides, among other things, methods and compositions for increasing UBE3A expression in cells, particularly cells that express UBE3A-ATS, which is encoded by the bottom (antisense) DNA strand at the Ube3a locus. Without wishing to be bound to any specific theory, the Ube3a locus is believed to be imprinted and, in the central nervous system, only the maternal allele is expressed. The paternal Ube3a allele is thought to be silenced by the Ube3a- ATS transcript. By targeting the Ube3a-ATS transcript for degradation in cells of the centralnervous system, the paternal Ube3a allele (which is usually silenced in those cells) becomes active in those cells which, in turn, increases the expression of UBE3A in those cells.

[0005] In one exemplary aspect, the disclosure provides nucleic acid cassettes that encode RNAs that are complementary to one or more regions of UBE3A-ATS.

[0006] These and other aspects will be described in greater detail below.INCORPORATION BY REFERENCE

[0007] All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.BRIEF DESCRIPTION OF THE DRAWINGS

[0008] Certain novel features of the invention may be set forth with particularity in the appended claims. A better understanding of some features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of some aspects of the invention are describes, and the accompanying drawings of which:

[0009] Figure 1 illustrates abundance of UBE3A-ATS (ATS) in iPSC derived glutamatergic neurons treated with AAV s encoding different oligonucleotides as indicated, plotted as mean with standard error of the mean (SEM) relative to the scrambled control.

[0010] Figure 2 illustrates abundance of UBE3A-ATS (ATS) in iPSC derived glutamatergic neurons treated with AAVs encoding different oligonucleotides as indicated, plotted as mean with SEM relative to the scrambled control.

[0011] Figure 3 illustrates abundance of UBE3A-ATS (ATS) in iPSC derived glutamatergic neurons treated with AAVs encoding different oligonucleotides as indicated, plotted as mean with SEM relative to the scrambled control.

[0012] Figure 4 illustrates abundance of UBE3A-ATS (ATS) in SI 15KOHeLa cells chemically transfected with plasmids encoding different oligonucleotides as indicated, plotted as mean with SEM relative to the scrambled control.

[0013] Figure 5 illustrates abundance of UBE3A-ATS (ATS) in SI 15KOHeLa cells electroporated with plasmids encoding different oligonucleotides as indicated, plotted as mean with SEM relative to the scrambled control.

[0014] Figure 6 illustrates expression levels of paternal UBE3A in iPSC derived glutamatergic neurons treated with AAV s encoding different oligonucleotides as indicated, plotted as mean with SEM relative to the scrambled control.

[0015] Figure 7 illustrates expression levels of paternal UBE3A in iPSC derived glutamatergic neurons treated with AAV s encoding different oligonucleotides as indicated, plotted as mean with SEM relative to the scrambled control.DEFINITIONS

[0016] As used herein, the singular' forms "a", "an" and "the" are intended to include the plural forms as well, unless the context clearly indicates otherwise. Furthermore, to the extent that the terms "including", "includes", "having", "has", "with", or variants thereof are used in either the detailed description and / or the claims, such terms are intended to be inclusive in a manner similar to the term "comprising".

[0017] The term "AAV" is an abbreviation for adeno-associated virus and may be used to refer to the virus itself or a derivative thereof. The term covers all serotypes, subtypes, and both naturally occurring and recombinant forms, except where required otherwise. The abbreviation "rAAV" refers to recombinant adeno-associated virus. The term "AAV" includes all serotypes of AAV, including AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV9.47, AAV9(hul4), AAV10, AAV11, AAV 12, AAV13, AAVrh8, AAVrhlO, AAV-DJ, and AAV- DJ8, and hybrids thereof (i.e., chimeric AAV vectors), as well as avian AAV, bovine AAV, canine AAV, equine AAV, primate AAV, non-primate AAV, and ovine AAV. The genomic sequences of various serotypes of AAV, as well as the sequences of the native terminal repeats (TRs), Rep proteins, and capsid subunits are known in the art. Such sequences may be found in the literature or in public databases such as GenBank. A "rAAV vector" as used herein refers to an AAV vector comprising a polynucleotide sequence not of AAV origin (i.e., a polynucleotide heterologous to AAV), typically a sequence of interest for the genetic transformation of a cell. In general, the heterologous polynucleotide is flanked by at least one, and generally by two, AAV inverted terminal repeat sequences (ITRs). An rAAV vector may either be single-stranded (ssAAV) or self-complementary (scAAV). See, e.g., Raj et al., Expert Rev Hematol. 2011 Oct; 4(5): 539-549. An "AAV virus" or "AAV viral particle" refers to a viral particle composed of at least one AAV capsid protein and an encapsidated polynucleotide rAAV vector. If the particle comprises a heterologous polynucleotide (i.e., a polynucleotide other than a wild-type AAVgenome such as a transgene to be delivered to a mammalian cell), it is typically referred to as an "rAAV viral particle" or simply an "rAAV particle". AAVs may comprise genome components and capsids from multiple serotypes (e.g., pseudotyped vectors). For example, an AAV may comprise the genome of serotype 2 (e.g., ITRs) packaged in the capsid from serotype 5 or serotype 9. Pseudotyped vectors may demonstrate improved transduction efficiency as well as altered tropism. In some cases, an AAV serotype that can cross the blood brain barrier or infect cells of the CNS is preferred. In some aspects, the recombinant AAV vector is AAV1, AAV8, AAV9, AAVDJ, or chimeric AAV comprising features of two or more of these serotypes. In various embodiments, the AAV vector is an AAV9 vector or an scAAV9 vector. In certain embodiments, the AAV vector is an AAV9 vector or an scAAV9 vector and comprises a heterologous nucleic acid flanked by ITRs from a AAV serotype other than AAV9. In certain embodiments, the AAV vector is an AAV9 vector or an scAAV9 vector and comprises a heterologous nucleic acid flanked by AAV serotype 2 ITRs (i.e., ITR2).

[0018] The term "about" or "approximately" means within an acceptable error range for the particular value as determined by one of ordinary skill in the art, which will depend in part on how the value is measured or determined, i.e., the limitations of the measurement system. For example, "about" can mean within one or more than one standard deviation, per the practice in the art. Alternatively, "about" can mean a range of up to 20%, up to 15%, up to 10%, up to 5%, or up to 1%) of a given value.

[0019] In any of the embodiments described herein, "comprising" may be replaced with "consisting essentially of" or "consisting of." For example, an embodiment in which a particular element is included using the open-ended term “comprising” encompasses embodiments in which the element is included using the more restrictive terms “consisting essentially of’ or “consisting of’.

[0020] The terms "determining", "measuring", "evaluating", "assessing", "assaying", "analyzing", and their grammatical equivalents can be used interchangeably herein to refer to any form of measurement and include determining if an element is present or not (for example, detection). These terms can include both quantitative and / or qualitative determinations. Assessing may be relative or absolute.

[0021] The term "expression" refers to the process by which a nucleic acid sequence or a polynucleotide is transcribed from a DNA template (such as into mRNA or other RNAtranscript) and / or the process by which a transcribed mRNA is subsequently translated into peptides, polypeptides, or proteins. Transcripts and encoded polypeptides may be collectively referred to as "gene product." If the polynucleotide includes introns or splice sites, e.g., is derived from genomic DNA, expression may include splicing of the mRNA in a eukaryotic cell.

[0022] An "expression cassette" refers to a nucleic molecule comprising one or more regulatory elements operably linked to a coding sequence (e.g., a gene or genes) for expression.

[0023] A “transgene” refers to a portion of a nucleic acid cassette that is designed to be expressed in a cell. In some embodiments, a transgene encodes functional RNA, e.g., an antisense RNA. In some embodiments, a transgene of the present disclosure encodes a therapeutic cargo, e.g., a therapeutic RNA.

[0024] The term "effective amount" or "therapeutically effective amount" refers to that amount of a composition described herein that is sufficient to affect the intended application, including but not limited to disease treatment, as defined below. The therapeutically effective amount may vary depending upon the intended treatment application (in a cell or in vivo), or the subject and disease condition being treated, e.g., the weight and age of the subject, the severity of the disease condition, the manner of administration and the like, which can readily be determined by one of ordinary skill in the art. The term also applies to a dose that will induce a particular response in a target cell. The specific dose will vary depending on the particular composition chosen, the dosing regimen to be followed, whether it is administered in combination with other compounds, timing of administration, the tissue to which it is administered, and the physical delivery system in which it is carried.

[0025] A "fragment" of a nucleotide or peptide sequence is meant to refer to a sequence that is less than that believed to be the "full-length" sequence.

[0026] A "functional fragment" of a DNA, RNA, or protein sequence refers to a biologically active fragment of the sequence that is shorter than the full-length or reference DNA, RNA, or protein sequence, but which retains at least one biological activity (either functional or structural) that is substantially similar to a biological activity of the full-length or reference DNA, RNA, or protein sequence.

[0027] The terms "host cell," "host cell line," and "host cell culture" are used interchangeably and refer to cells into which exogenous nucleic acid has been introduced, including the progeny of such cells. Host cells include "transformants" and "transformed cells," which include theprimary transformed cell and progeny derived therefrom without regard to the number of passages. Progeny may not be completely identical in nucleic acid content to a parent cell but may contain mutations. Mutant progeny that have the same function or biological activity as screened or selected for in the originally transformed cell are included herein.

[0028] The term "human derived" as used herein refers to sequences that are found in a human genome (or a human genome build), or sequences homologous thereto. A homologous sequence may be a sequence which has a region with at least 80% sequence identity (e.g., as measured by BLAST) as compared to a region of the human genome. For example, a sequence that has at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to a human sequence is deemed human derived. In some cases, a regulatory element contains a human derived sequence and a non-human derived sequence such that overall the regulatory element has low sequence identity to the human genome, while a part of the regulatory element has 100% sequence identity (or local sequence identity) to a sequence in the human genome.

[0029] The term "in vitro" refers to an event that takes places outside of a subject’s body. For example, an in vitro assay encompasses any assay run outside of a subject. In vitro assays encompass cell-based assays in which cells alive or dead are employed. In vitro assays also encompass a cell-free assay in which no intact cells are employed.

[0030] The term "in vivo" refers to an event that takes place in a subject's body.

[0031] An "isolated" nucleic acid refers to a nucleic acid molecule that has been separated from a component of its natural environment. An isolated nucleic acid includes a nucleic acid molecule contained in cells that ordinarily contain the nucleic acid molecule, but the nucleic acid molecule is present extrachromosomally, at a chromosomal location that is different from its natural chromosomal location, or contains only coding sequences.

[0032] As used herein, "operably linked", "operable linkage", "operatively linked", or grammatical equivalents thereof refer to juxtaposition of genetic elements, e.g., a promoter, an enhancer, a poly adenylation sequence, etc., wherein the elements are in a relationship permitting them to operate in the expected manner. For instance, a regulatory element, which can comprise promoter and / or enhancer sequences, is operatively linked to a coding region if the regulatory element helps initiate transcription of the coding sequence. There may be intervening residuesbetween the regulatory element and coding region so long as this functional relationship is maintained.

[0033] A "pharmaceutically acceptable carrier" refers to an ingredient in a pharmaceutical formulation or composition, other than an active ingredient, which is nontoxic to a subject. A pharmaceutically acceptable carrier includes, but is not limited to, a buffer, excipient, stabilizer, or preservative.

[0034] The terms "pharmaceutical formulation" or "pharmaceutical composition" refer to a preparation which is in such form as to permit the biological activity of an active ingredient contained therein to be effective, and which contains no additional components which are unacceptably toxic to a subject to which the formulation would be administered.

[0035] The term "regulatory element" refers to a nucleic acid sequence or genetic element which is capable of influencing (e.g., increasing, decreasing, or modulating) expression of an operably linked sequence, such as a gene, a coding sequence, or an RNA (e.g., an mRNA). Regulatory elements include, but are not limited to, promoter, enhancer, repressor, silencer, insulator sequences, an intron, UTR, an inverted terminal repeat (ITR) sequence, a long terminal repeat sequence (LTR), a stability element, a miRNA target site, a posttranslational response element, or a polyA sequence, or a combination thereof. Regulatory elements can function at the DNA and / or the RNA level, e.g., by modulating gene expression at the transcriptional phase, post- transcriptional phase, or at the translational phase of gene expression; by modulating the level of translation (e.g., stability elements that stabilize mRNA for translation), RNA cleavage, RNA splicing, and / or transcriptional termination; by recruiting transcriptional factors to a coding region that increase gene expression; by increasing the rate at which RNA transcripts are produced, increasing or decreasing the stability of RNA produced, and / or increasing the rate of protein synthesis from RNA transcripts; and / or by preventing RNA degradation and / or increasing its stability to facilitate protein synthesis. In an exemplary embodiment, a regulatory element refers to an enhancer, repressor, promoter, or a combination thereof, particularly an enhancer plus promoter combination or a repressor plus promoter combination. In exemplary embodiments, the regulatory element is derived from a human sequence.

[0036] In general, "sequence identity" or "sequence homology", which can be used interchangeably, refer to an exact nucleotide-to-nucleotide or amino acid-to-amino acid correspondence of two polynucleotides or polypeptide sequences, respectively. Two or moresequences (polynucleotide or amino acid) can be compared by determining their "percent identity", also referred to as "percent homology". The percent identity to a reference sequence (e.g., nucleic acid or amino acid sequence) may be calculated as the number of exact matches between two optimally aligned sequences divided by the length of the reference sequence and multiplied by 100. Conservative substitutions are not considered as matches when determining the number of matches for sequence identity. It will be appreciated that where the length of a first sequence (A) is not equal to the length of a second sequence (B), the percent identity of A:B sequence will be different than the percent identity of B:A sequence. Sequence alignments, such as for the purpose of assessing percent identity, may be performed by any suitable alignment algorithm or program, including but not limited to the Needleman-Wunsch algorithm, the BLAST algorithm, the Smith-Waterman algorithm (see, e.g., the EMBOSS Water aligner), and Clustal Omega alignment program (F. Sievers et al., Mol Sys Biol. 7: 539 (2011)). Optimal alignment may be assessed using any suitable parameters of a chosen algorithm, including default parameters. The BLAST program is based on the alignment method of Karlin and Altschul, Proc. Natl. Acad. Sci. USA 87:2264-2268 (1990) and as discussed in Altschul, et al., J. Mol. Biol. 215:403-410 (1990); Karlin and Altschul, Proc. Natl. Acad. Sci. USA 90:5873-5877 (1993); and Altschul et al., Nucleic Acids Res. 25:3389-3402 (1997).

[0037] The terms "subject" and "individual" are used interchangeably herein to refer to a vertebrate, preferably a mammal, more preferably a human. The methods described herein can be useful in human therapeutics, veterinary applications, and / or preclinical studies in animal models of a disease or condition.

[0038] As used herein, the terms "treat", "treatment", "therapy" and the like refer to obtaining a desired pharmacologic and / or physiologic effect, including, but not limited to, alleviating, delaying or slowing progression, reducing effects or symptoms, preventing onset, preventing reoccurrence, inhibiting, ameliorating onset of a diseases or disorder, obtaining a beneficial or desired result with respect to a disease, disorder, or medical condition, such as a therapeutic benefit and / or a prophylactic benefit. "Treatment," as used herein, covers any treatment of a disease in a mammal, particularly in a human, and includes: (a) preventing the disease from occurring in a subject which may be predisposed to the disease or at risk of acquiring the disease but has not yet been diagnosed as having it; (b) inhibiting the disease, i.e., arresting its development; and (c) relieving the disease, i.e., causing regression of the disease. A therapeuticbenefit includes eradication or amelioration of the underlying disorder being treated. Also, a therapeutic benefit is achieved with the eradication or amelioration of one or more of the physiological symptoms associated with the underlying disorder such that an improvement is observed in the subject, notwithstanding that the subject may still be afflicted with the underlying disorder. In some cases, for prophylactic benefit, the compositions are administered to a subject at risk of developing a particular disease, or to a subject reporting one or more of the physiological symptoms of a disease, even though a diagnosis of this disease may not have been made. The methods of the present disclosure may be used with any mammal. In some cases, the treatment can result in a decrease or cessation of symptoms. A prophylactic effect includes delaying or eliminating the appearance of a disease or condition, delaying or eliminating the onset of symptoms of a disease or condition, slowing, halting, or reversing the progression of a disease or condition, or any combination thereof.

[0039] A "variant" of a nucleotide sequence refers to a sequence having a genetic alteration or a mutation as compared to the most common wild-type DNA sequence (e.g., cDNA or a sequence referenced by its GenBank accession number) or a specified reference sequence. A variant can be shorter than the reference sequence and / or have one or more mutations relative to the reference sequence. In some cases, a variant may have a nucleotide sequence that is at least 80% identical, at least 90% identical or at least 95% identical to a reference sequence.

[0040] A "vector" as used herein refers to a nucleic acid molecule that can be used to mediate delivery of another nucleic acid molecule to which it is linked into a cell where it can be replicated or expressed. The term includes the vector as a self-replicating nucleic acid structure as well as the vector incorporated into the genome of a host cell into which it has been introduced. Certain vectors are capable of directing the expression of nucleic acids to which they are operatively linked. Such vectors are referred to herein as "expression vectors." Other examples of vectors include plasmids and viral vectors.

[0041] As used herein a “target cell” is generally a cell in which expression of RNA or protein product of the nucleic acid cassette is desired. A non-target cell is a cell in which expression of the RNA or protein product of the nucleic acid is not desired. As used herein “detargeting” generally refers to decreasing the expression in a non-target cell.

[0042] Unless otherwise indicated, all terms used herein have the same meaning as they would to one skilled in the art and the practice of the present invention will employ, conventionaltechniques of molecular biology, microbiology, and recombinant DNA technology, which are within the knowledge of those of skill of the art.DETAILED DESCRIPTION

[0043] Before the present invention is further described, it is to be understood that this invention is not limited to particular embodiments described, and as such may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present invention will be limited only by the appended claims.

[0044] The upper and lower limits of ranges may independently be included in the ranges, and are also encompassed within the invention, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the invention.

[0045] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present invention, the preferred methods and materials are now described. All publications mentioned herein are incorporated herein by reference to disclose and describe the methods and / or materials in connection with which the publications are cited.

[0046] It must be noted that as used herein and in the appended claims, the singular forms “a,” “an,” and “the” include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to “a protein” includes a plurality of such proteins and reference to “the nucleic acid” includes reference to one or more nucleic acids and equivalents thereof known to those skilled in the art, and so forth. It is further noted that the claims may be drafted to exclude any optional element. As such, this statement is intended to serve as antecedent basis for use of such exclusive terminology as “solely,” “only” and the like in connection with the recitation of claim elements, or use of a “negative” limitation.

[0047] It is appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the invention, which are, for brevity, described inthe context of a single embodiment, may also be provided separately or in any suitable subcombination. All combinations of the embodiments pertaining to the invention arc specifically embraced by the present invention and are disclosed herein just as if each and every combination was individually and explicitly disclosed. In addition, all sub-combinations of the various embodiments and elements thereof are also specifically embraced by the present invention and are disclosed herein just as if each and every such sub-combination was individually and explicitly disclosed herein.

[0048] The publications discussed herein are provided solely for their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention. Further, the dates of publication provided may be different from the actual publication dates which may need to be independently confirmed.

[0049] As summarized above, this disclosure describes methods and compositions for increasing UBE3A expression in cells wherein UBE3A-ATS is expressed. In one aspect, the present application provides nucleic acid cassettes which encode RNAs that are complementary to one or more regions of UBE3A-ATS. In another aspect, the present application provides oligonucleotides that are complementary to one or more regions of UBE3A-ATS.

[0050] An oligonucleotide of this disclosure may be between 15 and 40 nucleotides in length. In some cases, an oligonucleotide may be between 10 and 30 nucleotides in length. In some cases, an oligonucleotide is 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleotides in length.

[0051] The disclosed oligonucleotides can have a contiguous nucleotide sequence of 10 to 30 nucleotides in length with at least 80% complementary, at least 85%, at least 90%, at least 92%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or 100% complementarity to a sequence of UBE3A-ATS.

[0052] In some embodiments, this disclosure describes oligonucleotides which bind, target, or are complementary to a nucleotide sequence between positions 25,170,426 and 25,252,333 on human chromosome 15, according to Genome Reference Consortium Human Build 38, released 2013 / 12 / 17 (GRCh38.pl3), as deposited in GenBank as accession number NC_000015. In some embodiments, this disclosure describes oligonucleotides which bind, target, or are complementary to an RNA transcribed from a region between positions 25,170,426 and25,252,333 on human chromosome 15. In some embodiments, this disclosure describes oligonucleotides which bind, target, or arc complementary to an RNA comprising a region transcribed from a genomic sequence between positions 25,170,426 and 25,252,333 on human chromosome 15 according to GRCh38. The nucleotide sequence of an RNA transcribed from position 25,170,426 to position 25,252,333 on human chromosome 15 is also provided herein as SEQ ID NO: 1. In some embodiments, this disclosure describes oligonucleotides which bind, target, or are complementary to a nucleotide sequence within SEQ ID NO. 1.

[0053] An oligonucleotide may bind, or target, a sequence that is perfectly complementary to the oligonucleotide, or may bind to, or target, a sequence which includes mismatches in some positions relative to the genomic sequence. An oligonucleotide of this invention may be at least 80%, 85%, 90%, 95%, or 98% complementary to a 10-40 nucleotide sequence between positions 25,170,426 and 25,252,333 on human chromosome 15. An oligonucleotide of this invention may be at least 80%, 85%, 90%, 95%, or 98% complementary to a 10-30 nucleotide sequence between positions 25,170,426 and 25,252,333 on human chromosome 15. An oligonucleotide of this invention may be complementary to a 10-30 nucleotide sequence between positions 25,170,426 and 25,252,333 on human chromosome 15. An oligonucleotide of this invention may be at least 80%, 85%, 90%, 95%, or 98% complementary to a 10-30 nucleotide sequence located within SEQ ID NO: 1. In some cases, an oligonucleotide described herein may be complementary to a 10-30 nucleotide sequence located within SEQ ID NO: 1. An oligonucleotide of this invention may bind to a 10-30 nucleotide sequence located within SEQ ID NO: 1. In some cases, and oligonucleotide of this invention targets a 10-30 nucleotide sequence of SEQ ID NO: 1.

[0054] In some embodiments, this disclosure describes oligonucleotides which bind to, target, or are complementary to, a nucleotide sequence of a spliced or unspliced SNORD115 transcript. The oligonucleotide may bind within, or be complementary to a sequence within, a 3’ region, intron, exon or 5’ region of the SNORD115 transcript. In some cases, the oligonucleotide may target a 10-30 nucleotide sequence within, a 3’ region, intron, exon or 5’ region of the SNORD1 15 transcript. In some cases, the oligonucleotide may bind within, target, or be complementary, to a repeated sequence within a spliced or unspliced SNORD115 transcript. In some cases, the oligonucleotide may bind to, target, or be complementary to a repeated sequence within SEQ ID NO: 1. An oligonucleotide of this invention may be at least 80%, 85%, 90%,95%, or 98% complementary to at least 2, at least 3, at least 4, at least 5, at least 10, at least 20, at least 30, at least 40, or at least 50, 10-30 nucleotide sequences located within SEQ ID NO: 1. The at least 2, at least 3, at least 4, at least 5, at least 10, at least 20, at least 30, at least 40, or at least 50, 10-30 nucleotide sequences located within SEQ ID NO: 1 may be different sequences, or may be the same sequence but repeated multiple times within SEQ ID NO: 1. In some cases, an oligonucleotide described herein may be complementary to a 10-30 nucleotide sequence located within SEQ ID NO:1, wherein the 10-30 nucleotide sequence is repeated at least 2, at least 3, at least 4, at least 5, at least 10, at least 20, at least 30, at least 40, or at least 50 times within SEQ ID NO: 1. In some cases, an oligonucleotide of this invention may bind, target, or be at least 80%, 85%, 90%, 95%, or 98% complementary to a 10-30 nucleotide sequence located within SEQ ID NOs: 2, 3 77, or 78. In some cases, an oligonucleotide described herein may bind, target, or be complementary to a 10-30 nucleotide sequence located within SEQ ID Nos: 2, 3, 77 or 78.

[0055] In some cases, an oligonucleotide described herein binds to, or targets, a spliced or unspliced- SNORD115-E3 transcript. In some cases, an oligonucleotide described herein binds to, targets, or is complementary to a sequence of, any one of exons 139-143 of SNORD115-E3. An oligonucleotide of this invention may be at least 80%, 85%, 90%, 95%, or 98% complementary to a contiguous nucleotide sequence within any one of exons 139-143 of SNORD115-E3. An oligonucleotide of this invention may be at least 80%, 85%, 90%, 95%, or 98% complementary to a sequence located within any one of SEQ ID NOs: 4-8. In some cases, an oligonucleotide described herein may be complementary to a sequence located within any one of SEQ ID NOs: 4-8.

[0056] An oligonucleotide described herein may comprise a sequence at least 80%, 85%, 90%, 95%, or 98% identical to a sequence of any one of SEQ ID Nos: 9-38. An oligonucleotide described herein may comprise a sequence of any one of SEQ ID Nos: 9-38. In some cases, an oligonucleotide described herein may have a sequence of any one of SEQ ID Nos: 9-38. In some cases, an oligonucleotide described herein may comprise a sequence of any one of SEQ ID Nos: 9-38, and may also comprise an additional 1, 2, 3, 4, or 5 nucleotides which are complementary to the 1, 2, 3, 4, or 5 nucleotides surrounding the oligonucleotide binding site on SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, or 77. In some cases, an oligonucleotide of this disclosure may comprise a sequence complementary to a sequence located within SEQ ID NO: 1, wherein the sequencecomplementary to a sequence located within SEQ ID NO:1 comprises a fragment of any one of SEQ ID Nos: 9-38. In some cases, the oligonucleotide may be a walkthrough of an RNA binding site on SEQ ID NO: 1, wherein the binding site is complementary to any one of SEQ ID Nos 9- 38.

[0057] In some cases, the oligonucleotide is a non-naturally occurring oligonucleotide. Oligonucleotide design refers to the pattern of nucleoside sugar modifications in the oligonucleotide sequence. The disclosed antisense oligonucleotide may comprise sugar-modified nucleosides and may also comprise DNA, RNA, or arabino nucleic acid (ANA) nucleosides. In some embodiments, the oligonucleotide comprises sugar-modified nucleosides and DNA nucleosides. In some embodiments, the oligonucleotide comprises sugar-modified nucleosides and RNA nucleosides. In some embodiments, the oligonucleotide comprises sugar-modified nucleosides and ANA nucleosides.

[0058] In some embodiments, the oligonucleotide comprises at least 1 modified nucleoside, such as at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15 or at least 16 modified nucleosides. In an embodiment the oligonucleotide comprises from 1 to 10 modified nucleosides, such as from 2 to 9 modified nucleosides, such as from 3 to 8 modified nucleosides, such as from 4 to 7 modified nucleosides, such as 6 or 7 modified nucleosides.

[0059] In some embodiments, the oligonucleotide comprises at least one modified intemucleoside linkage. In some embodiments, the internucleoside linkages within the contiguous nucleotide sequence are phosphoro thioate or boranophosphate intemucleoside linkages.

[0060] In some embodiments, the oligonucleotide is an RNA and does not comprise a modified nucleoside. In some cases, an RNA may be chemically synthesized, or may be expressed in a cell from a DNA template. In some embodiments, an RNA as described herein may be an miRNA, a siRNA, a shRNA, or an RNA oligonucleotide.

[0061] Reference to an “RNA” in this disclosure, particularly reference an RNA that binds to a target sequence in another molecule such as an RNA transcript or a sequence on human chromosome 15, refers to an RNA molecule that can have an inhibitory effect on expression of the other molecule. Such inhibitory RNAs include, but are not limited to. antisense RNAs and inhibitory RNA (e.g., siRNAs and miRNAs). Such molecules are reviewed in a number of publications, including Hastings et al (RNA 2023 29: 393-395). Such RNA molecules can bemade synthetically. Alternatively, RNA can be encoded by a transgene. If a transgene “encodes” such an RNA, then the transgcnc may contain all of the necessary sequence elements to effect expression of the RNA, or a precursor of the same that will be processed by the cell’s endogenous machinery to produce the RNA.

[0062] Antisense oligonucleotides (ASOs) are small (-18-3O nucleotides) single-stranded nucleic acids of diverse chemistries, which can be employed to modulate gene expression via various mechanisms. ASOs can be subdivided into two major categories: RNase H competent and steric block. RnaseH competent ASOs comprise DNA. For RnaseH competent ASOs, the endogenous RNase H enzyme recognizes RNA-DNA heteroduplex substrates that are formed when DNA- based oligonucleotides bind to their cognate transcripts and catalyzes the degradation of the RNA. Cleavage at the site of ASO binding results in destruction of the target RNA, thereby silencing target gene expression.

[0063] Steric block oligonucleotides are typically RNA. These ASOs are designed to bind to target transcripts with high affinity but do not induce target transcript degradation as they lack RNase H competence. Steric block oligonucleotides can mask specific sequences within a target transcript and thereby interfere with transcript RNA-RNA and / or RNA-protein interactions. The most widely used application of steric block ASOs is in the modulation of alternative splicing in order to selectively exclude or retain a specific exon. In these cases, the oligonucleotide ‘masks’ a splicing signal such that it becomes invisible to the spliceosome, leading to alterations in splicing.

[0064] ASOs are typically made synthetically, in which case they may contain any number of chemical modifications, including nucleobase modifications, terminal modifications and ribose sugar modifications (e.g., 2'-O-methoxyethyl or 2'-O-methyl bases) and can be directly administered, e.g., using a lipid-based carrier such as lipid nanoparticles.

[0065] Silencing RNAs, on the other hand, target the RNA transcript to which they bind for translational repression, destabilization or degradation, typically via the RISC complex. miRNAs (microRNAs) and siRNAs (small interfering RNAs) are types of silencing RNAs. Silencing RNAs are typically produced by transcribing a longer hairpin molecule (referred to as a ‘pri- miRNA’ or ‘pre-miRNA’ in the case of miRNAs or a ‘shRNA’ (short hairpin RNA) in the case of siRNAs) from an expression cassette in a cell, which is then processed by the cell’s endogenous machinery. Pre- and pri-miRNAs are encoded by the human genome. miRNAs areinitially transcribed as longer primary transcripts (or termed pri-miRNAs), containing a 60- 120 nt RNA hairpin in which one of the two strands includes the miRNA. siRNAs can be designed using the sequence of a transcript. shRNAs have a 19-29 base pair stem, a small loop and 3 '-terminal overhang, typically a UU overhang. In both cases, the hairpin is subsequently processed by Dicer to produce a duplex of 21 to 23 nucleotides and a 3’ overhang. miRNAs have the same general structure as siRNAs, except that there may be mismatches in the duplex.Although either strand of the duplex may potentially act as a functional silencing RNA, only one strand is usually incorporated into the RNA-induced silencing complex (RISC) where the miRNA / siRNA and its target interact. Such molecules can also be produced by a ‘mature’ miRNA vector system that makes use of convergent promoters (e.g., the U6 and Hl promoters). A description of several strategies for expressing miRNAs and shRNAs can be found Fan et al (Cancer Gene Therapy 27: 424-437) and Herrera-Carrillo et al (Hum Gene Ther Methods 2017 28: 177-190).

[0066] Because strategies that rely on silencing RNA (particularly miRNAs) should be non- immunogenic and expression of the silencing RNA can be restricted to a particular tissue or celltype by the use a tissue-specific or cell type-specific promoter, therapies that are based on administering silencing RNAs have the potential to have less side effects in certain cases. Further, multiple silencing RNAs can, in theory, be encoded on a single vector, allowing a single transcript to be targeted by multiple different silencing RNAs. Finally, silencing RNA-based strategies should result in long term effects, because, in theory, the vector should persist in the cells and should not diffuse away or be degraded, which would be the case for certain other types of therapies.Repeated sequences

[0067] In some embodiments, an RNA may be described as binding to a sequence that is repeated in a longer sequence, i.e., a repeated sequence. In these embodiments, the term “repeated sequence element” refers to a sequence that is present at multiple places in a longer contiguous sequence, a “repeat containing sequence”. The repeated sequence element may be repeated with 100% sequence identity, or may be repeated with at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97 % at least, at least 98%, or at least 99% sequence identity in each instance of the repeated sequence element in the repeat containing sequence. A “repeated sequence element” may be a sequence that is at least 30 nt, at least 50 nt, at least 100nt, at least 200nt, at least 300 nt, or at least 400 nt in length. A “repeated sequence element” may be present in at least 2, at least 3, at least 5, at least 10, at least 15, at least 20, at least 25, at least 30, at least 40, at least 50, at least 60, or at least 100 places in a repeat containing sequence, where the sequences of the copies of the repeated sequence element may be, independently, at least 80%, at least 90%, or at least 95% identical to the sequence of a single instance of the repeated sequence element.

[0068] One example of a- repeated sequence element that is repeated in the sequence between nucleotides 25,170,426 and 25,252,333 of human chromosome 15 (i.e., SEQ ID NO: 1) is:CAGGCCCUUCCUCACACCCUGGUCUCCUGCACUAGCUGUGGUGAGCA CAUCCGGGUCCCGCUGGAUGCAUGCAAGAGGUGGUUGGUCUCGUGG GUUGGGUCGAUGAUGAGAACCUUAUAUUUUCCUGAAGAGAGGUGAU GACUUAAAAAUCAUGCUCAAUAGGAUUACGCUGAGGCCCAGCCUAG GUGAGAACUUUGGAAGSEQ ID NO: 2

[0069] This repeated sequence element corresponds to nucleotides 72796-72996 of SEQ ID NO: 1 and is 201 nucleotides in length. Allowing for up 34 mismatches (i.e., an approximately 17% variation in the sequence, at approximately 83% sequence identity), at least 35 copies of this repeated sequence element can be found in SEQ ID NO: 1, specifically at the following intervals: 76528-76727, 26751-26957, 16717-16917, 37265-37464, 7919-8120, 28646-28829, 9678-9879, 61569-61769, 78385-78580, 18592-18796, 35443-35644, 52431-52625, 69019-69220, 54384- 54583, 1819-2017, 20588-20798, 6015-6214, 22504-22703, 74673-74860, 14812-15013, 44726- 44923, 39103-39300, 63431-63629, 24121-24302, 47801-47998, 13487-13688, 32409-32609, 33539-33739, 70949-71128, 30505-30705, 40976-41176, 56287-56491, 80056-80241, 65267- 65467, 4114-4309, 42828-43030 and 60044-60217. Binding sites for SEQ ID Nos: 37, 12, .14, 35, 13, 36, 79, 80, 81, 17^ and 18 can be found in this repeated sequence. In other words, binding sites for SEQ ID Nos: 37, 12, 14, 35, 13, 36, 79, 80, 81, 17±and 18 can be found multiple times in SEQ ID NO: 1 because those binding sites can be found in SEQ ID NO: 2 and its copies in SEQ ID NO: 1, where the sequences of the copies are independently at least 83% identical to SEQ ID NO: 2.

[0070] Another example of a repeated sequence element that is repeated in SEQ ID NO: 1 is:UCUGAAGAGAGGUGAUGACUUAAAAAUCAUGCUCAAUAGGAUUACGCUGAGGCCCAGCCUAGGUGAGAAUUUSEQ ID NO: 3

[0071] This repeated sequence element corresponds to nucleotides 6,137-6,208 of SEQ ID NO: 1 and is 72 nucleotides in length. This sequence is repeated 6 times in SEQ ID 1 at 100% sequence identity. At an identity threshold of at least 85% sequence identity at least 44 copies of this repeated sequence element can be found in SEQ ID NO: 1, specifically at the following intervals: 6137 - 6208, 9802 - 9873, 16840 - 16911, 24225 - 24296, 26880 - 26951, 76650 - 76721, 29 - 99, 20722 - 20792, 28754 - 28824, 71052 - 71122, 13611 - 13682, 61692 - 61763, 8044 - 8114, 52552 - 52622, 69144 - 69214, 72920 - 72990, 78504 - 78574, 80165 - 80235, 1942 - 2011, 18720 - 18789, 37387 - 37458, 42953 - 43024, 14937 - 15007, 22627 - 22697, 39224 - 39294, 44847 - 44917, 47923 - 47993, 65391 - 65461, 63554 - 63623, 54508 - 54579, 74784 - 74852, 56415 - 56485, 58273 - 58343, 4233 - 4301, 35568 - 35637, 30629 - 30699, 32533 - 32603, 33663 - 33733, 60144 - 60214, 51652 - 51721, 11688 - 11757, 41103 - 41172, 49803 - 49872, and 67292 - 67362.

[0072] Binding sites for SEQ ID Nos: 35, 14, 13, 16, 12^ and 17 can be found in this sequence.

[0073] In another example, the following sequence can be found 14 times in SEQ ID NO: 1 at100% sequence identity:UUGUCCUGAAGAGAGGUGAUGACUUAAAAAUCAUGSEQ ID NO: 77

[0074] This repeated sequence element corresponds to nucleotides 4,228-4,262 of SEQ ID NO: 1 and is 35 nucleotides in length. At a sequence identity threshold of at least 80% at least 43 copies of this repeated sequence element can be found in SEQ ID NO: 1, specifically at the following intervals: 4228 - 4262, 8039 - 8073, 14932 - 14966, 18715 - 18749, 20717 - 20751, 35563 - 35597, 39219 - 39253, 44842 - 44876, 47918 - 47952, 52547 - 52581, 65386 - 65420, 71047 - 71081, 74779 - 74813, 78499 - 78533, 30624 - 30657, 32528 - 32561, 33658 - 33691, 24 - 58, 6133 - 6167, 9798 - 9832, 11683 - 11717, 22622 - 22656, 28749 - 28783, 56410 - 56444, 69139- 69173, 72915 - 72949, 76646 - 76680, 80160 - 80194, 26877 - 26910, 61689 - 61722, 16837 - 16870, 24222 - 24255, 1936 - 1970, 13607 - 13641, 37388 - 37417, 42949 - 42983, 49798 - 49832, 58268 - 58302, 60139 - 60173, 63548 - 63582, 51653 - 51682, 54504 - 54538, and 67287- 67321. At a sequence identity of at least 96% at least 26 copies of this repeated sequenceelement are found. Binding sites for SEQ ID Nos: 35, 16, 14, 13, and 12 can be found in this sequence.

[0075] In another example, the following sequence can be found 10 times in SEQ ID NO: 1 at least 80% sequence identity:GCACCCUGGUCUCCUGCACUGAGCUGUGGUGAGCACAUCCAGGUUCUGCU GGAUGCAUGCAUGGGGAGGGCCUUGAUUGGGUCAAUGAUGAGAACCUUA UAUSEQ ID NO: 78

[0076] This repeated sequence element corresponds to nucleotides 78,398-78,499 of SEQ ID NO: 1 and is 102 nucleotides in length. At a mismatch or gap for every 6 nucleotides (a sequence identity threshold of at least 83%) at least 10 copies of this repeated sequence element can be found in SEQ ID NO: 1, specifically at the following intervals: 1829-1936, 22,515-22622, 39,114-39,219, 54,397-54,504, 61,582-61,688, 69,032-69,139, 72,809-72,915, 74,672-74,779, 76,539-76,646, 78,398-78,499. Binding sites for SEQ ID Nos: 36 and 37 can be found in this sequence.

[0077] In some cases, an oligonucleotide described herein binds to, or targets, a sequence which is repeated within SEQ ID NO: 1 . In some cases, an oligonucleotide described herein binds to, targets, or is complementary to a sequence which is repeated within SEQ ID NO:1. An oligonucleotide of this invention may be at least 80%, 85%, 90%, 95%, or 98% complementary to a contiguous nucleotide sequence which is repeated within SEQ ID NO:1. An oligonucleotide of this invention may be at least 80%, 85%, 90%, 95%, or 98% complementary to a sequence which is repeated within SEQ ID NO:1. In some cases, an oligonucleotide described herein may be complementary to a sequence which is repeated within SEQ ID NO:1. The sequence repeated within SEQ ID NO: 1 may be repeated at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 15, at least 20, at least 30, at least 40, or at least 50 times within SEQ ID NO: 1. The sequence repeated within SEQ ID NO: 1 may be repeated with at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% sequence identity.

[0078] In some cases, an oligonucleotide described herein binds to, or targets, a sequence within one of more of SEQ ID Nos: 2, 3, 77, and 78. In some cases, an oligonucleotide described herein binds to, targets, or is complementary to a sequence of, any one of SEQ ID Nos: 2, 3, 77, and 78. An oligonucleotide of this invention may be at least 80%, 85%, 90%, 95%, or 98%complementary to a contiguous nucleotide sequence within any one of SEQ ID Nos: 2, 3, 77, and 78. An oligonucleotide of this invention may be at least 80%, 85%, 90%, 95%, or 98% complementary to a sequence located within any one of SEQ ID Nos: 2, 3, 77, and 78. In some cases, an oligonucleotide described herein may be complementary to a sequence located within any one of SEQ ID Nos: 2, 3, 77, and 78.Sliding Windows

[0079] Reference to an RNA “which binds a nucleotide sequence” in a longer sequence, e.g., in the sequence defined by nucleotides 25,170,426 and 25,252,333 of human chromosome 15 (i.e., SEQ ID NO: 1), or a transcript encoded by the same, refers to an RNA that binds to any subsequence within that longer sequence. The sub-sequence may be of any length, e.g., in the range of 10 nts to 1,000 nts, 10 nts to 100 nts, 10 nts to 50 nts or 10 nts to 30 nts in length (e.g., 15 to 25 nts in length), and may start at any position in the longer sequence. That is, the 5’ end of the sub-sequence may be at any position in the longer sequence, e.g., at position 1, 2, 3, 4, 5, etc.Mismatches

[0080] miRNAs are known to regulate gene expression by binding to a target sequence. miRNAs contain a seed sequence, which is a conserved heptametrical sequence which is situated at positions 2-7 from the 5 '-end of the miRNAs. The seed sequence should be perfectly complementary to the target sequence. The remainder of the miRNA sequence (i.e., the sequence that is 3’ to the seed sequence) can be less than perfectly complementary to the target sequence. As such, in many cases, an RNA that ‘binds’, ‘recognizes’ or ‘targets’ a longer sequence may, in some embodiments, comprise 6, 7, 8, 9 or 10 contiguous nucleotides that perfectly base pair with the target sequence at the 5’ end and a 3’ and that contains mismatches. In any embodiment, an RNA of the invention may contain 0, 1, 2, 3 or 4 mismatches relative to the sequence to which it binds, particularly towards the 3’ end.Transgenes

[0081] In some embodiments, this disclosure provides a transgene which encodes an RNA. The transgene may comprise a sequence encoding the RNA as described herein and sequences that enable expression and processing of the RNA. In some cases, the transgene comprises an miRNA scaffold sequence. In some cases, the transgene comprises a sequence encoding a pri-miRNA. Ins some cases, the transgene comprises a sequence encoding a pre-miRNA. In some cases, the transgcnc comprises a sequence encoding an shRNA.Nucleic acid cassettes

[0082] In some cases, a transgene may be contained within a nucleic acid cassette. A nucleic acid cassette may contain one or more additional regulatory elements (e.g., a promoter, a repressor, an insulator, a terminator, miRNA binding site, and / or an enhancer, etc.) that induces or represses expression of a transgene in a particular cell type, or a particular class of cell types. For instance, a cell type selective regulatory element can induce gene expression in a particular’ cell type relative to one or more- other cell types. Alternatively, or in addition, a cell type selective regulatory element can induce gene expression in a particular class of cells relative to one or more other classes of cells. In one embodiment, a cell type selective regulatory element of the invention enhances gene expression in a particular cell type, or a particular class of cells. In another embodiment, a cell type selective regulatory element suppresses gene expression in a particular cell type, or a particular class of cells. Cell type selective modulation of gene expression (e.g., enhancing or suppressing gene expression) does not require that gene expression is affected only in the target cell type or class of cells. Rather, cell type selective modulation of gene expression (e.g., enhancing or suppressing gene expression) requires only that gene expression increase, or decrease, in the target cell type relative to one or more other cell types, or classes of cells.

[0083] In certain embodiments, a promoter may be human derived or comprises a sequence that is human derived. In some cases, the promoter may be mouse derived or comprises a sequence that is mouse derived. In some cases, the promoter is non-naturally occurring or comprises a non- naturally occurring sequence. In some instances, the sequence of a promoter may be 100% human derived. In other instances, at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 98%, or 99% of the promoter sequence is human derived. For example, a promoter can have 50% of its sequence derived from human, and the remaining 50% be non-human derived (e.g., mouse derived or fully synthetic).

[0084] In certain embodiments, the nucleic acid constructs described herein comprise another regulatory element in an addition to a promoter, such as, for example, sequences associated with transcription initiation or termination, enhancer sequences, and efficient RNA processing signals. Exemplary regulatory elements include, for example, an intron, an enhancer, UTR, stabilityelement, WPRE sequence, a Kozak consensus sequence, or a combination thereof. Regulatory elements can function to modulate gene expression at the transcriptional phase or post- transcriptional phase of gene expression. At the RNA level, regulation can occur at the level of miRNA processing from pri-miRNA and pre-miRNA. In various embodiments, regulatory elements can recruit transcription factors that increase gene expression selectivity in a cell type of interest, increase the rate at which RNA transcripts are produced, and / or increase the rate of miRNA synthesis from RNA transcripts.

[0085] The cassette may be linear, circular and, in some embodiments, the nucleic acid cassette may be a vector such as a plasmid or viral vector, e.g., an adeno-associated virus (AAV) vector or lentiviral vector. The nucleic acid cassette may comprise sequences allowing for replication or packaging of the nucleic acid cassette. For example, a nucleic acid cassette may comprise viral vector sequences that allow for replication and / or packaging with capsid proteins. In certain embodiments, the viral vector may be an AAV vector selected from AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV9.47, AAV9(hul4), AAV10, AAV11, AAV 12, AAV13, AAVrh8, AAVrhlO, AAV-DI, and AAV-DI8, and hybrids thereof. In some embodiments, the nucleic acid cassette may comprise an AAV ITR sequence. The AAV ITR sequence may be selected from an AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV9.47, AAV9(hul4), AAV10, AAV11, AAV 12, AAV13, AAVrh8, AAVrhlO, AAV-DJ, or AAV-DJ8 ITR sequence, or may comprise a hybrid thereof. In some cases, the AAV ITR is an AAV2 ITR.

[0086] In any embodiment, the nucleic acid cassette may be non-naturally occurring, meaning that, for example, the miRNA sequence may be heterologous to the miRNA scaffold sequence. In any embodiment, the nucleic acid cassette may comprise a promoter and / or enhancer. In some embodiments, this nucleic acid cassette may be composed of a promoter, a coding sequence and a terminator, where the promoter, coding sequence and terminator are in operable linkage. In these embodiments, the promoter may be heterologous to the miRNA sequence, meaning that the promoter does not drive the expression of that miRNA sequence in a wild type cell. In any embodiment, the nucleic acid cassette may additionally comprise an enhancer.Vectors

[0087] Expression vectors may be used to deliver the nucleic acid molecule to a target cell via transfection or transduction. A vector may be an integrating or non-integrating vector, referringto the ability of the vector to integrate the expression cassette or transgene into the genome of the host cell. Examples of expression vectors include, but arc not limited to, (a) non- viral vectors such as nucleic acid vectors including linear oligonucleotides and circular plasmids; artificial chromosomes such as human artificial chromosomes (HACs), yeast artificial chromosomes (YACs), and bacterial artificial chromosomes (BACs or PACs)); episomal vectors; transposons (e.g., PiggyBac); and (b) viral vectors such as retroviral vectors, lentiviral vectors, adenoviral vectors, and adeno-associated viral vectors.

[0088] Expression vectors may be lineal’ oligonucleotides or circular plasmids and can be delivered to a cell via various transfection methods, including physical and chemical methods. Physical methods generally refer to methods of delivery employing a physical force to counteract the cell membrane barrier in facilitating intracellular delivery of genetic material. Examples of physical methods include the use of a needle, ballistic DNA, electroporation, sonoporation, photoporation, magnetofection, and hy droporation. Chemical methods generally refer to methods in which chemical carriers deliver a nucleic acid molecule to a cell and may include inorganic particles, lipid-based vectors, polymer-based vectors and peptide-based vectors.

[0089] In some embodiments, an expression vector is administered to a target cell using an inorganic particle. Inorganic particles may refer to nanoparticles, such as nanoparticles that are engineered for various sizes, shapes, and / or porosity to escape from the reticuloendothelial system or to protect an entrapped molecule from degradation. Inorganic nanoparticles can be prepared from metals (e.g., iron, gold, and silver), inorganic salts, or ceramics (e.g., phosphate or carbonate salts of calcium, magnesium, or silicon). The surface of these nanoparticles can be coated to facilitate DNA binding or targeted gene delivery. Magnetic nanoparticles (e.g., supermagnetic iron oxide), fullerenes (e.g., soluble carbon molecules), carbon nanotubes (e.g., cylindrical fullerenes), quantum dots and supramolecular systems may also be used.

[0090] In some embodiments, an expression vector is administered to a target cell using a cationic lipid (e.g., cationic liposome). Various types of lipids have been investigated for gene delivery, such as, for example, a lipid nano emulsion (e.g., which is a dispersion of one immiscible liquid in another stabilized by emulsifying agent) or a solid lipid nanoparticle.

[0091] In some embodiments, an expression vector is administered to a target cell using a peptide-based delivery vehicle. Peptide based delivery vehicles can have advantages of protecting the genetic material to be delivered, targeting specific cell receptors, disruptingendosomal membranes and delivering genetic material into a nucleus. Tn some embodiments, an expression vector is administered to a target cell using a polymer-based delivery vehicle.Polymer based delivery vehicles may comprise natural proteins, peptides and / or polysaccharides or synthetic polymers. In one embodiment, a polymer-based delivery vehicle comprises polyethylenimine (PEI). PEI can condense DNA into positively charged particles which bind to anionic cell surface residues and are brought into the cell via endocytosis. In other embodiments, a polymer based delivery vehicle may comprise poly-L-lysine (PLL), poly (DL-lactic acid) (PLA), poly ( DL-lactide-co-glycoside) (PLGA), polyomithine, polyarginine, histones, protamines, dendrimers, chitosans, synthetic amino derivatives of dextran, and / or cationic acrylic polymers. In certain embodiments, polymer-based delivery vehicles may comprise a mixture of polymers, such as, for example PEG and PLL.

[0092] In certain embodiments, an expression vector may be a viral vector suitable for gene therapy. Preferred characteristics of viral gene therapy vectors or gene delivery vectors may include the ability to be reproducibly and stably propagated and purified to high titres; to mediate targeted delivery (e.g., to deliver the transgene specifically to the tissue or organ of interest without widespread vector dissemination elsewhere); and to mediate gene delivery and transgene expression without inducing harmful side effects.

[0093] Several types of viruses, for example the non-pathogenic parvovirus referred to as adeno- associated virus, have been engineered for the purposes of gene therapy by harnessing the viral infection pathway but avoiding the subsequent expression of viral genes that can lead to replication and toxicity. Such viral vectors can be obtained by deleting all, or some, of the coding regions from the viral genome, but leaving intact those sequences (e.g., terminal repeat sequences) that may be necessary for functions such as packaging the vector genome into the virus capsid or the integration of vector nucleic acid (e.g., DNA) into the host chromatin.

[0094] In various embodiments, suitable viral vectors include retroviruses (e.g., A-type, B-type, C-type, and D-type viruses), adenovirus, parvovirus (e.g. adeno-associated viruses or AAV), coronavirus, negative strand RNA viruses such as orthomyxovirus (e.g., influenza virus), rhabdovirus (e.g., rabies and vesicular stomatitis virus), paramyxovirus (e. g. measles and Sendai), positive strand RNA viruses such as picomavirus and alphavirus, and double-stranded DNA viruses including adenovirus, herpesvirus (e.g., Herpes Simplex virus types 1 and 2, Epstein-Barr virus, cytomegalovirus), and poxvirus (e.g., vaccinia, fowlpox and canarypox).Examples of retroviruses include avian leukosis-sarcoma virus, human T-lymphotrophic virus type 1 (HTLV-1), bovine leukemia virus (BLV), lentivirus, and spumavirus. Other viruses include Norwalk virus, togavirus, flavivirus, reoviruses, papovavirus, hepadnavirus, and hepatitis virus, for example. Viral vectors may be classified into two groups according to their ability to integrate into the host genome - integrating and non- integrating. Oncoretroviruses and lentiviruses can integrate into host cellular chromatin while adenoviruses, adeno-associated viruses, and herpes viruses predominantly persist in the cell nucleus as extrachromosomal episomes.

[0095] In certain embodiments, a suitable viral vector is a retroviral vector. Retroviruses refer to viruses of the family Retroviridae. Examples of retroviruses include oncoretroviruses, such as murine leukemia virus (MLV), and lentiviruses, such as human immunodeficiency virus 1 (HIV- 1). Retroviral genomes are single-stranded (ss) RNAs and comprise various genes that may be provided in cis or trans. For example, retroviral genome may contain cis-acting sequences such as two long terminal repeats (LTR), with elements for gene expression, reverse transcription and integration into the host chromosomes. Other components include the packaging signal (psi or \| / ), for the specific RNA packaging into newly formed virions and the polypurine tract (PPT), the site of the initiation of the positive strand DNA synthesis during reverse transcription. In addition, the retroviral genome may comprise gag, pol and env genes. The gag gene encodes the structural proteins, the pol gene encodes the enzymes that accompany the ssRNA and carry out reverse transcription of the viral RNA to DNA, and the env gene encodes the viral envelope. Generally, the gag, pol and env arc provided in trans for viral replication and packaging.

[0096] In certain embodiments, a retroviral vector provided herein may be a lentiviral vector. At least five serogroups or serotypes of lentiviruses are recognized. Viruses of the different serotypes may differentially infect certain cell types and / or hosts. Lentiviruses, for example, include primate retroviruses and non-primate retroviruses. Primate retroviruses include HIV and simian immunodeficiency virus (SIV). Non-primate retroviruses include feline immunodeficiency virus (FIV), bovine immunodeficiency virus (BIV), caprine arthritisencephalitis virus (CAEV), equine infectious anemia virus (EIAV) and visnavirus. Lentiviruses or lentivectors may be capable of transducing quiescent cells. As with oncoretrovirus vectors, the design of lentivectors may be based on the separation of cis- and trans-acting sequences.

[0097] Tn exemplary embodiments, a viral vector provided herein is an adeno-associated virus (AAV). AAV is a small, replication-defective, non-cnvclopcd animal virus that infects humans and some other primate species. AAV is not known to cause human disease and induces a mild immune response. AAV vectors can also infect both dividing and quiescent cells without integrating into the host cell genome.

[0098] The AAV genome consists of a linear single stranded DNA which is ~4.7kb in length. The genome consists of two open reading frames (ORF) flanked by an inverted terminal repeat (ITR) sequence that is about 145bp in length. The ITR consists of a nucleotide sequence at the 5’ end (5’ ITR) and a nucleotide sequence located at the 3’ end (3’ ITR) that contain palindromic sequences. The ITRs function in cis by folding over to form T-shaped hairpin structures by complementary base pairing that function as primers during initiation of DNA replication for second strand synthesis. The two open reading frames encode for rep and cap genes that are involved in replication and packaging of the virion. In an exemplary embodiment, an AAV vector provided herein does not contain the rep or cap genes. Such genes may be provided in trans for producing virions as described further below.

[0099] In certain embodiments, an AAV vector may include a stuffer nucleic acid. In some embodiments, the stuffer nucleic acid may encode a green fluorescent protein or antibiotic resistance gene such as kanamycin or ampicillin. In certain embodiments, the stuffer nucleic acid may be located outside of the ITR sequences (e.g., as compared to the polynucleotide encoding a therapeutic protein, and regulatory sequences, which are located between the 5’ and 3’ ITR sequences).

[0100] Various serotypes of AAV exist, including AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV9.47, AAV9(hul4), AAV10, AAV11, AAV 12, AAV13, AAVrh8, AAVrhlO, AAV-DJ, and AAV-DJ8. These serotypes differ in their tropism, or the types of cells they infect. AAVs may comprise the genome and capsids from multiple serotypes (e.g., pseudotypes). For example, an AAV may comprise the genome of serotype 2 (e.g., ITRs) packaged in the capsid from serotype 5 or serotype 9. Pseudotypes may improve transduction efficiency as well as alter tropism.

[0101] In some embodiments, an AAV vector or an AAV viral particle, or virion, may be used to deliver a construct comprising a cell selective regulatory element operably linked to a polynucleotide encoding functional therapeutic protein into a cell, cell type, or tissue, and maydone either in vivo, ex vivo, or in vitro. In exemplary embodiments, such an AAV vector is replication-deficient. In some embodiments, an AAV virus is engineered or genetically modified so that it can replicate and generate virions only in the presence of helper factors.

[0102] In certain embodiments, a viral vector can be selected to produce a virion having high infectivity without selectivity for a particular cell type. In some cases, an AAV serotype that can cross the blood brain barrier or infect cells of the CNS is preferred.

[0103] In exemplary embodiments, the application provides expression vectors that have been designed for delivery by an AAV. The AAV can be any serotype, for examples, AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV9.47, AAV9(hul4), AAV 10, AAV11, AAV 12, AAV13, AAVrh8, AAVrhlO, AAV-DJ, and AAV-DJ8, or a chimeric, hybrid, or variant AAV. The AAV can also be a self-complementary AAV (scAAV), where a “self- complementary” AAV is one in which the coding region has been designed to form an intramolecular double-stranded DNA template. Upon infection of such vectors, rather than waiting for cell mediated synthesis of the second strand, the two complementary halves of the scAAV will associate to form one double stranded DNA (dsDNA) unit that is ready for immediate replication and transcription. The design of scAAV vectors is described in a variety of publications, including McCarty et al Gene Therapy 2001 8: 1248-54.

[0104] In certain embodiments, an expression vector designed for delivery by an AAV comprises a 5’ ITR and a 3’ ITR. In certain embodiments, an expression vector designed for delivery by an AAV comprises a 5’ ITR, a promoter, a construct as described above and a 3’ ITR. In certain embodiments, an expression vector designed for delivery by an AAV comprises a 5’ ITR, an enhancer, a promoter, a construct as described above and a 3’ ITR.Method for reducing expression of UBE3A-ATS

[0105] In some embodiments, the present disclosure provides methods of reducing expression of UBE3A-ATS in a cell wherein UBE3A-ATS is expressed. The methods may comprise contacting the cell with an oligonucleotide of this disclosure, an RNA of this disclosure, or a nucleic acid cassette or vector of this disclosure. The method of reducing expression of UBE3A- ATS may result in reduced expression compared to a comparable cell not treated with the oligonucleotide, RNA, nucleic acid cassette or vector. In some cases, the expression of UBE3A- ATS may be reduced by about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%,about 80%, about 85%, about 90%, about 95%, about 97%, or about 98% as compared to expression of UBE3A-ATS in a comparable cell not treated with the oligonucleotide, RNA, nucleic acid cassette or vector. In some cases, the expression of UBE3A-ATS may be reduced by at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, or at least 98% as compared to expression of UBE3A-ATS in a comparable cell not treated with the oligonucleotide, RNA, nucleic acid cassette or vector. In some cases, the expression of UBE3A-ATS may be reduced by about 5% to about 95%, about 10% to about 90%, about 10% to about 80%, about 10% to about 50%, about 15% to about 50%, or about 15% to about 50%, as compared to expression of UBE3A-ATS in a comparable cell not treated with the oligonucleotide, RNA, nucleic acid cassette or vector. The reduction in expression of UBE3A-ATS may be assessed by standard molecular techniques, including quantitative polymerase chain reaction.

[0106] In some embodiments, the present disclosure provides methods of increasing expression of UBE3A mRNA or protein in a cell wherein UBE3A-ATS is expressed. The methods may comprise contacting the cell wherein UBE3A-ATS is expressed with an oligonucleotide of this disclosure, an RNA of this disclosure, or a nucleic acid cassette or vector of this disclosure. The method of increasing expression of UBE3A may result in increased expression compared to a comparable cell not treated with the oligonucleotide, RNA, nucleic acid cassette or vector. In some cases, the expression of UBE3A may be increased by about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 97%, or about 98% as compared to expression of UBE3A in a comparable cell not treated with the oligonucleotide, RNA, nucleic acid cassette or vector. In some cases, the expression of UBE3A may be increased by at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, or at least 98% as compared to expression of UBE3A in a comparable cell not treated with the oligonucleotide, RNA, nucleic acid cassette or vector. In some cases, the expression of UBE3A may be increased by about 5% to about 95%, about 10% to about 90%, about 10% to about 80%, about 10% to about 50%, about 15% to about 50%, or about 15% to about 50%, as compared to expression ofUBE3A in a comparable cell not treated with the oligonucleotide, RNA, nucleic acid cassette or vector. The increase in expression of UBE3A may be assessed by standard molecular techniques, including quantitative polymerase chain reaction and western blot analysis.

[0107] In some embodiments, the present disclosure provides methods of increasing expression of paternal UBE3A mRNA, or protein, in a cell wherein UBE3A-ATS is expressed. The methods may comprise contacting the cell wherein UBE3A-ATS is expressed with an oligonucleotide of this disclosure, an RNA of this disclosure, or a nucleic acid cassette or vector of this disclosure. The method of increasing expression of paternal UBE3A may result in increased expression of paternal UBE3A compared to a comparable cell not treated with the oligonucleotide, RNA, nucleic acid cassette or vector. In some cases, the expression of paternal UBE3A may be increased by about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 97%, or about 98% as compared to expression of paternal UBE3A in a comparable cell not treated with the oligonucleotide, RNA, nucleic acid cassette or vector. In some cases, the expression of paternal UBE3A may be increased by at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, or at least 98% as compared to expression of paternal UBE3A in a comparable cell not treated with the oligonucleotide, RNA, nucleic acid cassette or vector. In some cases, the expression of paternal UBE3A may be increased by about 5% to about 95%, about 10% to about 90%, about 10% to about 80%, about 10% to about 50%, about 15% to about 50%, or about 15% to about 50%, as compared to expression of paternal UBE3A in a comparable cell not treated with the oligonucleotide, RNA, nucleic acid cassette or vector. In some cases, the expression of paternal UBE3A may be increased by at least 1.5 fold, 2 fold, 3 fold, 4 fold, 5 fold, 6 fold, 7 fold, 8 fold, 9 fold, 10 fold, 12 fold, 14 fold, 15 fold, or more than 15 fold as compared to expression of paternal UBE3A in a comparable cell not treated with the oligonucleotide, RNA, nucleic acid cassette or vector. The increase in expression of paternal UBE3A may be assessed by standard molecular techniques in cells where there are polymorphisms between the maternal and paternal UBE3A alleles. Such techniques include next generation sequencing.

[0108] Tn some embodiments, a cell in which: expression of UBE3A-ATS is decreased, expression of UBE3A is increased, or expression of paternal UBE3A is increased may be a cultured cell or an in vitro cell. In some cases, the cell is a primary neuron, an IPSC derived neural cell, a neuronal cell line, and engineered cell line, or a neural stem cell. Contacting a cultured cell or an in vitro cell may comprise introducing the oligonucleotide, RNA, nucleic acid cassette or vector to the culture medium. In some cases, the cell is an in vivo cell. For example, a neuron such as a central nervous system neuron. In some cases, contacting the in vivo cell may comprise introducing the oligonucleotide, RNA, nucleic acid cassette or vector into the blood stream or the cerebral spinal fluid. The oligonucleotide, RNA, nucleic acid cassette or vector may be introduced into the cerebral spinal fluid by intraparenchymal injection, intrathecal injection, intra-cisterna magna injection, or intraccrcbrovcntricular injection.Pharmaceutical compositions

[0109] Also disclosed are pharmaceutical compositions comprising any of the aforementioned viruses, vectors, expression cassettes, oligonucleotides and / or oligonucleotide conjugates and a pharmaceutically acceptable diluent, carrier, salt and / or adjuvant. A pharmaceutically acceptable diluent includes phosphate-buffered saline (PBS) and pharmaceutically acceptable salts include, but are not limited to, sodium and potassium salts. In some embodiments, the diluent is artificial cerebrospinal fluid (aCSF).

[0110] The disclosed viruses, vectors, expression cassettes, or oligonucleotides may be mixed with pharmaceutically acceptable active or inert substances for the preparation of pharmaceutical compositions or formulations. Compositions and methods for the formulation of pharmaceutical compositions are dependent upon a number of criteria, including, but not limited to, route of administration, extent of disease, or dose to be administered.

[0111] Those skilled in the art are aware of a variety of formulation strategies useful for storage and / or administration of viruses, vectors, expression cassettes, and nucleic acid therapeutics such as oligonucleotide therapeutics.Methods of treatment

[0112] Also disclosed are methods for treating or preventing a neurological condition, disorder, or disease, comprising administering a therapeutically or prophylactically effective amount of a pharmaceutical composition comprising an oligonucleotide, RNA, nucleic acid cassette, or vector, disclosed herein to a subject suffering from or susceptible to the disease.

[0113] Also disclosed is use of the disclosed oligonucleotides for the manufacture of a medicament for the treatment of a disorder as referred to herein, or for a method of the treatment of as a disorder as referred to herein.

[0114] The disclosed pharmaceutical compositions may be administered by topical (such as, to the skin, inhalation, ophthalmic or otic) or enteral (such as, orally or through the gastrointestinal tract) or parenteral (such as, intravenous, subcutaneous, intra-muscular, intracerebral, intracerebroventricular or intrathecal) administration. In some embodiments, the disclosed pharmaceutical compositions are administered by a parenteral route including intravenous, intraarterial, subcutaneous, intraperitoneal or intramuscular injection or infusion, intrathecal or intracranial, e.g., intracerebral or intraventricular, administration. In some embodiments, the oligonucleotide is administered by intracerebral or intracerebroventricular injection. In another embodiment the active oligonucleotide or oligonucleotide conjugate is administered intrathecally. In some embodiments, the pharmaceutical composition is administered by intracistemae magna injection.

[0115] In some embodiments, therapy with pharmaceutical compositions described herein is administered to subject(s) suffering from or susceptible to Angelman syndrome (AS). In some embodiments, a subject has been determined to have genetic characteristic associated with a defect in a maternal UBE3A gene. In some embodiments, an AS-associated genetic characteristic is, or comprises, a maternal deletion. In some embodiments, an AS-associated genetic characteristic is, or comprises, uniparental disomy. In some embodiments, an AS-associated genetic characteristic is, or comprises, a UBE3A mutation. In some embodiments, an AS- associated genetic characteristic is, or comprises, an imprinting defect.

[0116] Table 1 provides sequences of genes, genomic regions, and oligonucleotides referenced in this disclosure. SEQ ID NO; 1 can be found in the sequence listing.

[0117] Table IEMBODIMENTS

[0118] Exemplary embodiments are listed below /

[0119] Embodiment 1. A nucleic acid cassette comprising a transgene encoding an RNA that binds a nucleotide sequence between positions 25,170,426 and 25,252,333 on human chromosome 15.

[0120] Embodiment 2. The nucleic acid cassette of embodiment 1, wherein the RNA binds a repeated sequence between positions 25,170,426 and 25,252,333 on human chromosome 15.

[0121] Embodiment 3. The nucleic acid cassette of embodiment 1 or 2, wherein the RNA is at least 90% complementary to a 10-30 nucleotide sequence between positions 25,170,426 and 25,252,333 on human chromosome 15.

[0122] Embodiment 4. The nucleic acid cassette of any prior embodiment, wherein the RNA is at least 95% complementary to a 10-30 nucleotide sequence between positions 25,170,426 and 25,252,333 on human chromosome 15.

[0123] Embodiment 5. The nucleic acid cassette of any prior embodiment, wherein the RNA is complementary to a 10-30 nucleotide sequence between positions 25,170,426 and 25,252,333 on human chromosome 15, with the optional exception of 1, 2, 3 or 4 mismatches.

[0124] Embodiment 6. A nucleic acid cassette comprising a transgene encoding an RNA that binds a region of UBE3A-ATS that contains a SNORD115 transcript.

[0125] Embodiment 7. The nucleic acid cassette of embodiment 6, wherein the RNA binds a repeated sequence in the region of UBE3A-ATS that contains the SNORD115 transcript.

[0126] Embodiment 8. The nucleic acid cassette of embodiment 6 or 7, wherein the RNA is at least 90% complementary to a 10-30 nucleotide sequence in the region of UBE3A-ATS that contains the SNORD115 transcript.

[0127] Embodiment 9. The nucleic acid cassette of any of embodiments 6-8, wherein the RNA is at least 95% complementary to a 10-30 nucleotide sequence in the region of UBE3A-ATS that contains the SNORD115 transcript.

[0128] Embodiment 10. The nucleic acid cassette of any of embodiments 6-9, wherein the RNA is complementary to a 10-30 nucleotide sequence in the region of UBE3A-ATS that contains the SNORD115 transcript, with the optional exception of 1, 2, 3 or 4 mismatches.

[0129] Embodiment 11. A nucleic acid cassette comprising a transgene encoding an RNA that binds a spliced or unspliced SNORD115 transcript.

[0130] Embodiment 12. The nucleic acid cassette of embodiment 11, wherein the RNA binds within a 3’ region, intron, exon or 5’ region of the SNORD115 transcript.

[0131] Embodiment 13. The nucleic acid cassette of embodiment 11 or 12, wherein the RNA binds a repeated sequence of the spliced or unspliced SNORD115 transcript.

[0132] Embodiment 14. The nucleic acid cassette of any one of embodiments 11-13, wherein the RNA is at least 90% complementary to a 10-30 nucleotide sequence in the spliced or unspliced SNORD115 transcript.

[0133] Embodiment 15. The nucleic acid cassette of any of embodiments 11-14, wherein the RNA is at least 95% complementary to a 10-30 nucleotide sequence in the spliced or unspliced SNORD115 transcript.

[0134] Embodiment 16. The nucleic acid cassette of any of embodiments 11-15, wherein the RNA is complementary to a 10-30 nucleotide sequence in the spliced or unspliced SNORD115 transcript with the optional exception of 1, 2, 3 or 4 mismatches.

[0135] Embodiment 17. A nucleic acid cassette comprising a transgene encoding an RNA that binds to a 10-30 nucleotide sequence of SEQ ID NO. 1.

[0136] Embodiment 18. The nucleic acid cassette of embodiment 17, wherein a 10 to 30 nucleotide sequence of the RNA is at least 90% complementary to the 10-30 nucleotide sequence of SEQ ID NO. 1.

[0137] Embodiment 19. The nucleic acid cassette of embodiment 17 or 18, wherein a 10 to 30 nucleotide sequence of the RNA is at least 95% complementary to the 10-30 nucleotide sequence of SEQ ID NO. 1.

[0138] Embodiment 20. The nucleic acid cassette of any of embodiments 17-19, wherein a 10 to 30 nucleotide sequence of the RNA is complementary to the 10-30 nucleotide sequence of SEQ ID NO. 1, with the optional exception of 1, 2, 3 or 4 mismatches.

[0139] Embodiment 21. The nucleic acid cassette of any of embodiments 17-20, wherein the RNA is at least 90% complementary to a 10-30 nucleotide sequence of SEQ ID NO. 1.

[0140] Embodiment 22. The nucleic acid cassette of any of embodiments 17-21, wherein the RNA is at least 95% complementary to a 10-30 nucleotide sequence of SEQ ID NO. 1.

[0141] Embodiment 23. The nucleic acid cassette of any of embodiments 17-22, wherein the RNA is complementary to a 10-30 nucleotide sequence of SEQ ID NO. 1, with the optional exception of 1, 2, 3 or 4 mismatches.

[0142] Embodiment 24. A nucleic acid cassette comprising a transgene encoding an RNA that targets SEQ ID NO: 2, 3, 77 or 78.

[0143] Embodiment 25. The nucleic acid cassette of embodiment 25, wherein the RNA is at least 90% complementary to a 10-30 nucleotide sequence of SEQ ID NO.: 2, 3, 77, or 78.

[0144] Embodiment 26. The nucleic acid cassette of embodiment 25 or 26, wherein the RNA is at least 95% complementary to a 10-30 nucleotide sequence of SEQ ID NO.: 2, 3, 77, or 78.

[0145] Embodiment 27. The nucleic acid cassette of any of embodiments 24-26, wherein the RNA is complementary to a 10-30 nucleotide sequence of SEQ ID NO.: 2, 3, 77, or 78, with the optional exception of 1, 2, 3 or 4 mismatches.

[0146] Embodiment 28. A nucleic acid cassette comprising a transgene encoding an RNA wherein the RNA comprises at least 90% sequence identity to SEQ ID NO.: 9-38.

[0147] Embodiment 29. The nucleic acid cassette of embodiment 29, wherein the RNA comprises at least 95% sequence identity to SEQ ID NO.: 9-38.

[0148] Embodiment 30. The nucleic acid cassette of embodiment 29, wherein the RNA comprises a sequence of SEQ ID NO: 9-38, with the optional exception of 1, 2, 3 or 4 mismatches.

[0149] Embodiment 31. A nucleic acid cassette comprising a transgene comprising a sequence having at least 90% sequence identity to SEQ ID NO.: 40-70.

[0150] Embodiment 32. The nucleic acid cassette of embodiment 32, wherein the transgene comprises a sequence having at least 95% sequence identity to SEQ ID NO.: 40-70.

[0151] Embodiment 33. The nucleic acid cassette of embodiment 31 or 32, wherein the transgene comprises a sequence of SEQ ID NO.: 40-70, with the optional exception of 1, 2, 3 or 4 mismatches.

[0152] Embodiment 34. A nucleic acid cassette comprising a transgene encoding an RNA that binds a nucleotide sequence between positions 2526643 land 25271534 on human chromosome 15.

[0153] Embodiment 35. The nucleic acid cassette of embodiment 34, wherein the miRNA is at least 90% complementary to a 10-30 nucleotide sequence between positions 2526643 land 25271534 on human chromosome 15.

[0154] Embodiment 36. The nucleic acid cassette of embodiment 34 or 35, wherein the RNA is at least 95% complementary to a 10-30 nucleotide sequence between positions 2526643 land 25271534 on human chromosome 15.

[0155] Embodiment 37. The nucleic acid cassette of any of embodiments 34-36, wherein the RNA is complementary to a 10-30 nucleotide sequence between positions 25266431 and 25271534 on human chromosome 15, with the optional exception of 1, 2, 3 or 4 mismatches.

[0156] Embodiment 38. A nucleic acid cassette comprising a transgene encoding a RNA that binds to a 10-30 nucleotide sequence of SEQ ID NO.: 4, 5, 6, 7, or 8.

[0157] Embodiment 39. The nucleic acid cassette of embodiment 38, wherein a 10 to 30 nucleotide sequence of the RNA is at least 90% complementary to a 10-30 nucleotide sequence of SEQ ID NO. 4, 5, 6, 7, or 8.

[0158] Embodiment 40. The nucleic acid cassette of embodiment 38 or 39, wherein a 10 to 30 nucleotide sequence of the RNA is at least 95% complementary to a 10-30 nucleotide sequence of SEQ ID NO. 4, 5, 6, 7, or 8.

[0159] Embodiment 41 . The nucleic acid cassette of any of embodiments 38-40, wherein a 10 to 30 nucleotide sequence of the RNA is complementary to a 10-30 nucleotide sequence of SEQ ID NO. 4, 5, 6, 7, or 8, with the optional exception of 1, 2, 3 or 4 mismatches.

[0160] Embodiment 42. The nucleic acid cassette of any of embodiments 38-41, wherein the RNA is at least 90% complementary to a 10-30 nucleotide sequence of SEQ ID NO. 4, 5, 6, 7, or 8.

[0161] Embodiment 43. The nucleic acid cassette of any of embodiments 38-42, wherein the RNA is at least 95% complementary to a 10-30 nucleotide sequence of SEQ ID NO. 4, 5, 6, 7, or 8.

[0162] Embodiment 44. The nucleic acid cassette of any of embodiments 38-43, wherein the RNA is complementary to a 10-30 nucleotide sequence of SEQ ID NO. 4, 5, 6, 7, or 8, with the optional exception of 1, 2, 3 or 4 mismatches.

[0163] Embodiment 45. The nucleic acid cassette of any one of embodiments 1-44, wherein the RNA is a miRNA, an shRNA or an RNA antisense oligonucleotide.

[0164] Embodiment 46. The nucleic acid cassette of any one of embodiments 1-45, wherein the nucleic acid cassette is non-naturally occurring.

[0165] Embodiment 47. The nucleic acid cassette of any one of embodiments 1-46, wherein the nucleic acid cassette is DNA.

[0166] Embodiment 48. The nucleic acid cassette of any one of embodiments 1-47, wherein the nucleic acid cassette comprises a promoter.

[0167] Embodiment 49. The nucleic acid cassette of any one of embodiments 1-48, wherein the nucleic acid cassette comprises an enhancer.

[0168] Embodiment 50. The nucleic acid cassette of any one of embodiments 1-49, wherein the nucleic acid cassette comprises a miRNA scaffold.

[0169] Embodiment 51. The nucleic acid cassette of any one of embodiments 1-50, wherein the nucleic acid cassette is a linear construct.

[0170] Embodiment 52. A vector comprising the nucleic acid cassette of any one of embodiments 1-51.

[0171] Embodiment 53. The vector of embodiment 52, wherein the vector is a plasmid.

[0172] Embodiment 54. The vector of embodiment 52, wherein the vector is a viral vector.

[0173] Embodiment 55. The vector of embodiment 54, wherein the viral vector is an adeno- associatcd virus (AAV) vector.

[0174] Embodiment 56. The vector of embodiment 55, wherein the AAV is AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, or AAV-DJ.

[0175] Embodiment 57. The vector of embodiment 55 or 56, wherein the AAV is an scAAV.

[0176] Embodiment 58. The vector of embodiment 54, wherein the viral vector is a lentiviral vector.

[0177] Embodiment 59. A method of reducing expression of UBE3A-ATS in a cell, comprising contacting the cell with an effective amount of a nucleic acid cassette of any one of embodiments 1-51 or the vector of any one of embodiments 52-58.

[0178] Embodiment 60. The method of embodiment 59, wherein expression of UBE3A-ATS in the cell is reduced compared to a comparable cell not treated with the nucleic acid cassette of any one of embodiments 1-51 or the vector of any one of embodiments 52-58.

[0179] Embodiment 61. The method of embodiment 59 or 60, wherein the contacting the cell with an effective amount of the nucleic acid cassette of any one of embodiments 1-51, or the vector of any one of embodiments 52-58, results in at least a 5% reduction in UBE3A-ATS in the cell compared to a comparable untreated cell.

[0180] Embodiment 62. The method of any of embodiments 59-61, wherein the contacting the cell with an effective amount of the nucleic acid cassette of any one of embodiments 1-51, or the vector of any one of embodiments 52-58, results in at least a 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90% or 95% reduction in UBE3A- ATS in the cell compared to a comparable untreated cell.

[0181] Embodiment 63. The method of any of embodiments 59-62, wherein reduction in UBE3- ATS is measured by quantitative polymerase chain reaction.

[0182] Embodiment 64. An in vivo or in vitro method for inducing ubiquitin-protein ligase E3A (UBE3A) expression in a cell where UBE3A-ATS is expressed, the method comprising administering an effective amount of a nucleic acid cassette of any one of embodiments 1-51, or the vector of any one of embodiments 52-58, to the cell.

[0183] Embodiment 65. The method of embodiment 64, wherein expression of UBE3A in the cell is increased compared to a comparable cell not treated with the nucleic acid cassette of any one of embodiments 1-51, or the vector of any one of embodiments 52-58.

[0184] Embodiment 66. The method of embodiment 64 or 65, wherein expression of UBE3A in the cell is increased by at least 1.5 fold, 2, fold, 3 fold, or more than 3 fold compared to a comparable untreated cell.

[0185] Embodiment 67. The method of any of embodiments 64-66, wherein expression of paternal UBE3A in the cell is increased compared to a comparable cell not treated with the nucleic acid cassette of any one of embodiments 1-51, or the vector of any one of embodiments 52-58.

[0186] Embodiment 68. The method of embodiment 67, wherein expression of paternal UBE3A in the cell is increased by at least 1.5 fold, 2, fold, 3 fold, 4 fold, 6 fold, 7 fold, 8 fold, 9 fold, 10 fold, or more than 10 fold compared to a comparable untreated cell.

[0187] Embodiment 69. The method of any one of embodiments 59-68, wherein the cell is a cultured cell.

[0188] Embodiment 70. The method of embodiment 69, wherein the cell is a primary neuron, an IPSC derived neural cell, a neuronal cell line, an engineered cell line or a neural stem cell.

[0189] Embodiment 71. The method of any one of embodiments 59-68, wherein the cell is in vivo.

[0190] Embodiment 72. The method of embodiment 71, wherein the cell is a neuron.

[0191] Embodiment 73. The method of embodiment 71, wherein the cell is a neuron in the central nervous system (CNS), or a cell in contact with cerebral spinal fluid.

[0192] Embodiment 74. The method of any one of embodiments 59-73, wherein contacting the cell comprises delivering the nucleic acid cassette to the CNS or cerebral spinal fluid (CSF).

[0193] Embodiment 75. The method of any one of embodiments 59-74, wherein contacting the cell comprises delivering the nucleic acid cassette by intraparenchymal injection, intrathecal injection, intra-cisterna magna injection, or intracerebroventricular injection.

[0194] Embodiment 76. A method for treating or preventing a neurological condition or disorder in a subject comprising administering a therapeutically or prophylactically effective amount of a pharmaceutical composition comprising a nucleic acid cassette of any one of embodiments 1-51, or the vector of any one of embodiments 52-58.

[0195] Embodiment 77. The method of embodiment 76, wherein the neurological condition or disorder is Angelman syndrome.

[0196] Embodiment 78. The method of embodiment 76, wherein the method comprises administering the pharmaceutical composition to the subject via intrap arcnchymal injection, intrathecal injection, intra-cistema magna injection, intravenous injection, or intracerebroventricular injection.

[0197] Embodiment 79. A use of the nucleic acid cassette of any one of embodiments 1-51, or the vector of any one of embodiments 52-58, in the manufacture of a medicament for the treatment of a neurological condition or disorder.

[0198] Embodiment 80. A method of inducing expression of paternal UBE3A in a cell where expression of paternal UBE3A is suppressed, comprising administering to the cell an oligonucleotide that is at least 90% complementary to a 10-30 nucleotide sequence of an mRNA expressed from a region between positions 25,170,426 and 25,252,333 on human chromosome 15.

[0199] Embodiment 81. The method of embodiment 80, wherein the oligonucleotide comprises an RNA backbone, a DNA backbone, a modified backbone, or a combination of one of more backbones.

[0200] Embodiment 82. A method of inducing expression of paternal UBE3A in a cell where expression of paternal UBE3A is suppressed, comprising administering to the cell an oligonucleotide of at least 90% complementary to a 10-30 nucleotide sequence between positions 25,170,426 and 25,252,333 on human chromosome 15, a shRNA comprising a sequence at least 90% complementary to a 10-30 nucleotide sequence between positions 25,170,426 and 25,252,333 on human chromosome 15, or a nucleic acid capable of expressing an RNA comprising a sequence at least 90% complementary to a 10-30 nucleotide sequence between positions 25,170,426 and 25,252,333 on human chromosome 15.

[0201] Embodiment 83. A method of inducing expression of paternal UBE3A in a cell where expression of paternal UBE3A is suppressed, comprising administering to the cell an oligonucleotide of SEQ ID Nos: 9-38, a shRNA comprising a sequence of SEQ ID Nos: 9-38, or a nucleic acid capable of expressing an RNA comprising a sequence of SEQ ID NO.: 9-38.

[0202] In any embodiment, the RNA may have the sequence of SEQ ID NO: 12.EX MPI.ESEXAMPLE 1: RNA OLIGONUCLEOTIDE SCREENING

[0203] Oligonucleotide sequences capable of decreasing UBE3A-ATS expression were identified by designing sequences complementary to regions of the UBE3A-ATS and screening for activity in iPSC derived neural cells.

[0204] Oligonucleotide sequences were designed to be complementary to various regions of the UBE3A-ATS transcript. For administration of the oligonucleotides an AAV virus approach was used. Briefly, nucleic acid cassettes were designed incorporating a promoter, a miRNA scaffold, and a sequence encoding the desired oligonucleotide. AAV particles were produced for each of SEQ ID Nos: 9-38 and a scrambled control sequence SEQ ID NO: 39 using the AAV serotype AAVDJ.

[0205] iPSC glutamatergic neurons were purchased from Fujifilm Cellular Dynamics (iCell GlutaNeurons, 01279 (Catalog #: R10) and thawed according to the manufacturer’s directions. A 96 well plate was precoated with 0.01% Poly-L-Ornithine (PLO) and 0.28 mg / mL Matrigel (Coming Life Sciences). Cells were plated at 60,000 cells / well in the precoated 96 well plate.50% of the culture media was replaced at after 24 hours, and AAVs were added to the respective wells, diluted according to the multiplicity of infection (MOI) calculations. Further control wells were transduced with an AAV expressing green fluorescent protein under the control of a chicken beta actin promoter (AAVDJ-CBA-GFP) and monitored until DIV4-5 for general cell health. Additionally, scrambled miRNA treated neurons and unmanipulated neurons were also taken along as controls. Neurons were maintained according to manufacturer’s protocol, with 50% media replaced every 48h, until they were harvested at DIV8 (7-day transduction).

[0206] The iPSC derived glutamatergic neurons were infected with AAV encoding SEQ ID Nos. 15, 17-19, and 39, at a MOI of 10A6. Biological replicates were included for each construct.RNA was extracted using an RNAeasy kit (Qiagen) and ~40ng was used for cDNA generation using a VILO Superscript IV kit (ThermoFisher Scientific). qPCR was set up with Reverse Transcriptase + (RT+, template) and Reverse Transcriptase- (RT-, control) conditions for each sample using SYBR green based detection of amplification. The following primer sets were used for each target: UBE3A-ATS (SEQ ID Nos: 72-73), GAPDH (SEQ ID Nos: 74-75). Delta-delta Ct method was used to calculated expression of UBE3A-ATS and UBE3A relative to scrambled control treated neurons.

[0207] The results of this experiment are shown in Figure 1 , which shows strong knock down of UBE3A-ATS expression by SEQ ID Nos: 17, 18 and 19 as compared to the scrambled sequence (SEQ ID NO: 39). SEQ ID NO: 15 shows a trend towards knockdown.EXAMPLE 2: RNA OLIGONUCLEOTIDE SCREENING

[0208] A second experiment comprised two biological replicates with two technical transduction replicates performed. Cells for each biological replicate were plated and transduced one day apart. iPSC derived glutamatergic neurons were plated at 5X10A5 cells per well in 24 well tissue culture plates, pretreated as in Example 1. 100% of the culture media was replaced at 24h postplating and DIV1 neurons were transduced with AAVs at an MOI of 10A6. Neurons were maintained with a 100% media exchange every other day after the transduction, until harvest at 7 days post-transduction (DIV8).

[0209] Several control conditions were included in this experiment. As described in Example 1, a well was transduced with AAVDJ-CBA-GFP at an MOI of 10A6 to monitor general cell health and AAV-driven expression until DIV8 harvest. Three different non-targeting scrambled control miRNAs (SEQ ID Nos; 39, 76 and 77) were included.

[0210] UBE3A-ATS RNA levels were quantified using a qPCR assay. Briefly, RNA was extracted using Qiagen AllPrep DNA / RNA micro kit. 120 ng total RNA was used for cDNA generation using VILO Superscript IV kit (ThermoFisher Scientific). qPCR was set up with template (RT+) and control (RT-) conditions for each sample using SYBR green based detection of amplification. The primers were as per Example 1. The delta-delta Ct method was used to calculated expression of UBE3A-ATS, first normalized to GAPDH control and then relative to scramble control miRNA (SEQ ID NO: 39) treated sample.

[0211] The results of this experiment are shown in Figure 2, which shows strong knock down of UBE3A-ATS expression by all constructs except SEQ ID Nos: 24 and 25.EXAMPLE 3: RNA OLIGONUCLEOTIDE SCREENING

[0212] A further experiment was conducted using the same conditions as Example 2. Cells for each biological replicate were plated and transduced one day apart. Cells were thawed, plated, infected, cultured, and RNA extracted ,and analyzed, as above. The AAVs used expressed oligonucleotides of SEQ ID Nos: 12-14, 16, 22, 26-29, 32 and 38 (scrambled control). The UBE3A-ATS expression (relative to the scrambled control) is shown in Figure 3. Most of theconstructs exhibited high levels of UBE3A-ATS knockdown, particularly SEQ ID Nos: 12, 22, 27, 30 and 32 which all resulted in more than 50% knockdown. Further analysis of SEQ ID NO: 16 revealed the presence of a transcription termination sequence within the oligonucleotide encoding sequence, which may account for the failure of this construct to show UBE3A-ATS knockdown.EXAMPLE 4: OLIGONUCLEOTIDE SCREENING IN HELA CELLS

[0213] To broaden the assays beyond iPSC derived neurons a HeLa-cell based model was developed. HeLa cells do not usually express UBE3A-ATS, however deletion of the region from 24,958,811-25,264,503 of chromosome 15 results in expression of UBE3A-ATS. Creation of a HeLa cell line with a CRISPR mediated knockout of the genome region 24,958,811- 25,264,503 of chromosome 15 allowed transfection with plasmids containing the nucleic acid cassettes of Example 1, rather than AAV. This experiment comprised of 2 transfection replicates. Cells were plated at 50,000 cells per well in tissue culture plates. 500ng miR-E plasmid DNA and lOOng mCherry plasmid was transfected into each well with Eugene transfection reagent at a ratio of 3:1 (Fugene:DNA).

[0214] 72h post transfection, cells were harvested in RLT+BME lysis buffer and processed with RNAeasy Plus extraction kit (Qiagen). 160ng total RNA was used for cDNA generation using VILO Superscript IV kit (ThermoFisher Scientific). qPCR was set up with template (RT+) and control (RT-) conditions for each sample using SYBR based detection of amplification, as primers as above. Data were analyzed with delta delta Ct method and all samples were normalized to scrambled control miRNA (SEQ ID NO: 76).

[0215] Results from this experiment are shown in Figure 4. Both oligonucleotides tested, SEQ ID Nos: 33 and 34 resulted in strong knockdown of UBE3A-ATS by approximately 50%.EXAMPLE 5: ELECTROPORATION OF HELA CELLS

[0216] This experiment comprised of 2 biological replicates that were set up on different days, each with 1 electroporation replicate, in HeLa SI 15KO cells. 0.125ug of oligonucleotide expressing plasmid DNA was electroporated into each reaction of 150,000 cells / reaction using pulse code CM- 130 on Lonza Nucleofector X-unit. puc57 plasmid was used as filler DNA to electroporate a total of 0.5ug DNA with 10% GFP plasmid co-transfection. Immediately after electroporation, cells were rescued with 70uL of pre- warmed complete DMEM culture mediaand plated directly into 24-well plates. Cells were incubated at 37C for 3 days (3 cell divisions) without any media change and with daily monitoring of cell health and transfection efficiency. 72h post-electroporation, cells were harvested in RLT+BME lysis buffer and processed with RNAeasy Plus extraction kit (Qiagen). 160ng total RNA was used for cDNA generation using VILO Superscript IV kit (ThermoFisher Scientific). qPCR was set up with template (RT+) and control (RT-) conditions for each sample using SYBR based detection of amplification, using primers as above. Data were analyzed with delta delta Ct method and all samples were normalized to scrambled control miRNA. As shown in Figure 5, the oligonucleotide of SEQ ID No: 20 resulted in strong knockdown of UBE3A-ATS expression, achieving more than a 25% reduction.EXAMPLE 6: RESCUE OF UBE3A EXPRESSION

[0217] To determine expression of UBE3A in response to UBE3A-ATS knockdown an experiment was conducted in iPSC derived GABAergic neurons (Fujifilm Cellular Dynamics) which contained a polymorphism in one allele of the UBE3A gene. 250,000 cells / well were plated in a 24-well plate, pre-coated with 0.01% PLO and 10 pg / ml laminin. 100% of the culture media was replaced at D1V1. AAVs, expressing oligonucleotides as described in Example 1, were diluted according to the MOI calculator and added to the respective wells. Scrambled miRNA treated neurons and unmanipulated neurons were included as controls. Neurons were maintained according to manufacturer’s protocol, with 50% media replaced every 3-5 days, until they were harvested at DIV21 (20-day transduction).

[0218] RNA was extracted using RNAeasy micro kit (Qiagen) and ~40ng of RNA was used for cDNA generation using VILO Superscript IV kit (ThermoFisher Scientific). ddPCR was set up with template (RT+) and control (RT-) conditions. A UBE3A allele- specific probe set (ThermoFisher Scientific, Assay ID: ANYMTRK) was used to assay paternal and maternal UBE3A transcripts, taking advantage of a SNP present in UBE3A of the cell donor. This experiment comprised biological replicates plated across different days.

[0219] As shown in Figure 6, all of the oligonucleotides resulted in strong upregulation of paternal UBE3A expression. SEQ ID NO: 20 resulted in more than 2 fold upregulation of paternal UBE3A expression, while SEQ ID Nos: 13, 14, 35 and 36 all resulted in more than 3 fold upregulation and SEQ ID NO: 12 achieved a more than 4 fold upregulation of paternal UBE3A.

[0220] A further experiment was performed to screen oligonucleotides of SEQ ID Nos: 38, 79, 80 and 81. AAVs expressing an RNA oligonucleotide of SEQ ID Nos: 38, 79, 80 and 81 were generated. iPSC derived gabaergic neurons (iCell GABANeurons, 01434 (Catalog #: R1013)) were plated in 96 well tissue culture plates, and DIV 1 neurons were transduced with AAV at an MOI of 10A6. Neurons were maintained with a 50% media exchange every other day after the transduction, until harvest 13 days post-transduction (DIV14).

[0221] Paternal UBE3A and UBE3A-ATS RNA levels were quantified using ddPCR assays.Briefly, cells were lysed using ThermoFisher Cells-to-Ct kit and lysate used for cDNA generation using Cells-to-Ct reagents according to manufacturer's protocols. ddPCR was set up with template (RT+) and control (RT-) conditions for each sample and Taqman probes were used for target detection. Paternal UBE3A allelic frequency was calculated by dividing paternal UBE3A by the sum of paternal and maternal UBE3A. Relative UBE3A-ATS expression was calculated by first normalizing to GAPDH control and then relative to unmanipulated control samples.

[0222] Expression of the oligonucleotide of SEQ ID NO: 38 in the iPSC derived gabaergic neurons resulted in a paternal UBE3A allelic frequency of -39% indicating strong knockdown of UBE3A-ATS and rescue of paternal UBE3A expression. Further, expression of the oligonucleotide of SEQ ID NO: 38 resulted in relative UBE3A-ATS expression of -13% relative to unmanipulated control samples. Expression of the oligonucleotides of SEQ ID Nos: 79-81 in the iPSC derived gabaergic neurons did not result in a significantly increased paternal UBE3A allele frequency.EXAMPLE 7: RESCUE OF UBE3A EXPRESSION

[0223] Similarly to Example 6, iPSC derived GABAergic neurons were thawed and plated in a 96-well plate at 60,000 cells / well. The 96-well plate was pre-coated with 0.01% PLO and 10 pg / ml laminin. The experiment comprised of 3 biological replicates plated across different days. 100% culture media was replaced at DIVE AAVs diluted to a MOI of 10A6 according to the MOI calculator were added to the respective wells. Scrambled miRNA treated neurons and unmanipulated neurons were included as controls. Neurons were maintained according to manufacturer’s protocol, with 50% media replaced every 3-5 days, until they were harvested at DIV14 (13-day transduction).

[0224] Cells were harvested using Cells to Ct kit (Catalog number: AMI 729) and lysates used with RT reaction reagents provided in the kit to generate cDNA. ddPCR was set up with template (RT+) and control (RT-) conditions. A UBE3A allele- specific (Assay ID: ANYMTRK) probe set was used to assay paternal and maternal UBE3A transcripts, taking advantage of a SNP present in UBE3A of the cell donor.

[0225] As shown in Figure 7, the oligonucleotides of SEQ ID Nos: 12, 20 and 37 all induced strong upregulation of paternal UBE3A, with SEQ ID Nos: 12 and 37 both resulting in more than 3-fold upregulation.

Claims

CL IMSWhat is claimed is:

1. A nucleic acid cassette comprising a transgene encoding an RNA that binds a nucleotide sequence between positions 25,170,426 and 25,252,333 on human chromosome 15.

2. The nucleic acid cassette of claim 1, wherein the RNA binds a repeated sequence between positions 25,170,426 and 25,252,333 on human chromosome 15.

3. The nucleic acid cassette of claim 1 or 2, wherein the RNA is at least 90% complementary to a 10-30 nucleotide sequence between positions 25,170,426 and 25,252,333 on human chromosome 15.

4. The nucleic acid cassette of any prior claim, wherein the RNA is at least 95% complementary to a 10-30 nucleotide sequence between positions 25,170,426 and 25,252,333 on human chromosome 15.

5. The nucleic acid cassette of any prior claim, wherein the RNA is complementary to a 10- 30 nucleotide sequence between positions 25,170,426 and 25,252,333 on human chromosome 15, with the optional exception of 1, 2, 3 or 4 mismatches.

6. A nucleic acid cassette comprising a transgene encoding an RNA that binds a region of UBE3A-ATS that contains a SNORD115 transcript.

7. The nucleic acid cassette of claim 6, wherein the RNA binds a repeated sequence in the region of UBE3A-ATS that contains the SNORD115 transcript.

8. The nucleic acid cassette of claim 6 or 7, wherein the RNA is at least 90% complementary to a 10-30 nucleotide sequence in the region of UBE3A-ATS that contains the SNORD115 transcript.

9. The nucleic acid cassette of any of claims 6-8, wherein the RNA is at least 95% complementary to a 10-30 nucleotide sequence in the region of UBE3A-ATS that contains the SNORD115 transcript.

10. The nucleic acid cassette of any of claims 6-9, wherein the RNA is complementary to a 10-30 nucleotide sequence in the region of UBE3A-ATS that contains the SNORD115 transcript, with the optional exception of 1, 2, 3 or 4 mismatches.

11. A nucleic acid cassette comprising a transgene encoding an RNA that binds a spliced or unspliced SNORD115 transcript.

12. The nucleic acid cassette of claim 11, wherein the RNA binds within a 3’ region, intron, exon or 5’ region of the SNORD115 transcript.

13. The nucleic acid cassette of claim 11 or 12, wherein the RNA binds a repeated sequence of the spliced or unspliced SNORD115 transcript.

14. The nucleic acid cassette of any one of claims 11-13, wherein the RNA is at least 90% complementary to a 10-30 nucleotide sequence in the spliced or unspliced SNORD115 transcript.

15. The nucleic acid cassette of any of claims 11-14, wherein the RNA is at least 95% complementary to a 10-30 nucleotide sequence in the spliced or unspliced SNORD115 transcript.

16. The nucleic acid cassette of any of claims 11-15, wherein the RNA is complementary to a 10-30 nucleotide sequence in the spliced or unspliced SNORD115 transcript with the optional exception of 1, 2, 3 or 4 mismatches.

17. A nucleic acid cassette comprising a transgene encoding an RNA that binds to a 10-30 nucleotide sequence of SEQ ID NO. 1.

18. The nucleic acid cassette of claim 17, wherein a 10 to 30 nucleotide sequence of the RNA is at least 90% complementary to the 10-30 nucleotide sequence of SEQ ID NO. 1.

19. The nucleic acid cassette of claim 17 or 18, wherein a 10 to 30 nucleotide sequence of the RNA is at least 95% complementary to the 10-30 nucleotide sequence of SEQ ID NO. 1.

20. The nucleic acid cassette of any of claims 17-19, wherein a 10 to 30 nucleotide sequence of the RNA is complementary to the 10-30 nucleotide sequence of SEQ ID NO. 1, with the optional exception of 1, 2, 3 or 4 mismatches.

21. The nucleic acid cassette of any of claims 17-20, wherein the RNA is at least 90% complementary to a 10-30 nucleotide sequence of SEQ ID NO. 1.

22. The nucleic acid cassette of any of claims 17-21, wherein the RNA is at least 95% complementary to a 10-30 nucleotide sequence of SEQ ID NO. 1.

23. The nucleic acid cassette of any of claims 17-22, wherein the RNA is complementary to a 10-30 nucleotide sequence of SEQ ID NO. 1, with the optional exception of 1, 2, 3 or 4 mismatches.

24. A nucleic acid cassette comprising a transgene encoding an RNA that targets SEQ ID NO: 2, 3, 77 or 78.

25. The nucleic acid cassette of claim 24, wherein the RNA is at least 90% complementary to a 10-30 nucleotide sequence of SEQ ID NO.: 2, 3, 77, or 78.

26. The nucleic acid cassette of claim 24 or 25, wherein the RNA is at least 95% complementary to a 10-30 nucleotide sequence of SEQ ID NO.: 2, 3, 77, or 78.

27. The nucleic acid cassette of any of claims 24-26, wherein the RNA is complementary to a 10-30 nucleotide sequence of SEQ ID NO.: 2, 3, 77, or 78, with the optional exception of 1, 2, 3 or 4 mismatches.

28. A nucleic acid cassette comprising a transgene encoding an RNA wherein the RNA comprises at least 90% sequence identity to SEQ ID NO.: 9-38.

29. The nucleic acid cassette of claim 28, wherein the RNA comprises at least 95% sequence identity to SEQ ID NO.: 9-38.

30. The nucleic acid cassette of claim 28, wherein the RNA comprises a sequence of SEQ ID NO: 9-38, with the optional exception of 1, 2, 3 or 4 mismatches.31 . A nucleic acid cassette comprising a transgene comprising a sequence having at least 90% sequence identity to SEQ ID NO.: 40-70.

32. The nucleic acid cassette of claim 31, wherein the transgene comprises a sequence having at least 95% sequence identity to SEQ ID NO.: 40-70.

33. The nucleic acid cassette of claim 31 or 32, wherein the transgene comprises a sequence of SEQ ID NO.: 40-70, with the optional exception of 1, 2, 3 or 4 mismatches.

34. A nucleic acid cassette comprising a transgene encoding an RNA that binds a nucleotide sequence between positions 2526643 land 25271534 on human chromosome 15.

35. The nucleic acid cassette of claim 34, wherein the miRNA is at least 90% complementary to a 10-30 nucleotide sequence between positions 2526643 land 25271534 on human chromosome 15.

36. The nucleic acid cassette of claim 34 or 35, wherein the RNA is at least 95% complementary to a 10-30 nucleotide sequence between positions 25266431and 25271534 on human chromosome 15.

37. The nucleic acid cassette of any of claims 34-36, wherein the RNA is complementary to a 10-30 nucleotide sequence between positions 25266431 and 25271534 on human chromosome 15, with the optional exception of 1, 2, 3 or 4 mismatches.

38. A nucleic acid cassette comprising a transgene encoding a RNA that binds to a 10-30 nucleotide sequence of SEQ ID NO.: 4, 5, 6, 7, or 8.

39. The nucleic acid cassette of claim 38, wherein a 10 to 30 nucleotide sequence of the RNA is at least 90% complementary to a 10-30 nucleotide sequence of SEQ ID NO. 4, 5, 6, 7, or 8.

40. The nucleic acid cassette of claim 38 or 38, wherein a 10 to 30 nucleotide sequence of the RNA is at least 95% complementary to a 10-30 nucleotide sequence of SEQ ID NO. 4, 5, 6, 7, or8.41 . The nucleic acid cassette of any of claims 38-40, wherein a 10 to 30 nucleotide sequence of the RNA is complementary to a 10-30 nucleotide sequence of SEQ ID NO. 4, 5, 6, 7, or 8, with the optional exception of 1, 2, 3 or 4 mismatches.

42. The nucleic acid cassette of any of claims 38-41, wherein the RNA is at least 90% complementary to a 10-30 nucleotide sequence of SEQ ID NO. 4, 5, 6, 7, or 8.

43. The nucleic acid cassette of any of claims 38-42, wherein the RNA is at least 95% complementary to a 10-30 nucleotide sequence of SEQ ID NO. 4, 5, 6, 7, or 8.

44. The nucleic acid cassette of any of claims 38-43, wherein the RNA is complementary to a 10-30 nucleotide sequence of SEQ ID NO. 4, 5, 6, 7, or 8, with the optional exception of 1, 2, 3 or 4 mismatches.

45. The nucleic acid cassette of any one of claims 1-44, wherein the RNA is a miRNA, an shRNA or an RNA antisense oligonucleotide.

46. The nucleic acid cassette of any one of claims 1-45, wherein the nucleic acid cassette is non-naturally occurring.

47. The nucleic acid cassette of any one of claims 1-45, wherein the nucleic acid cassette is DNA.

48. The nucleic acid cassette of any one of claims 1-46, wherein the nucleic acid cassette comprises a promoter.

49. The nucleic acid cassette of any one of claims 1-48, wherein the nucleic acid cassette comprises an enhancer.

50. The nucleic acid cassette of any one of claims 1-49, wherein the nucleic acid cassette comprises a miRNA scaffold.

51. The nucleic acid cassette of any one of claims 1-50, wherein the nucleic acid cassette is a linear construct.

52. A vector comprising the nucleic acid cassette of any one of claims 1-51.

53. The vector of claim 52, wherein the vector is a plasmid.

54. The vector of claim 52, wherein the vector is a viral vector.

55. The vector of claim 54, wherein the viral vector is an adeno-associated virus (AAV) vector.

56. The vector of claim 55, wherein the AAV is AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, or AAV-DJ.

57. The vector of claim 55 or 56, wherein the AAV is an scAAV.

58. The vector of claim 54, wherein the viral vector is a lentiviral vector.

59. A method of reducing expression of UBE3A-ATS in a cell, comprising contacting the cell with an effective amount of a nucleic acid cassette of any one of claims 1-51 or the vector of any one of claims 52-58.

60. The method of claim 59, wherein expression of UBE3A-ATS in the cell is reduced compared to a comparable cell not treated with the nucleic acid cassette of any one of claims 1- 51 or the vector of any one of claims 52-58.

61. The method of claim 59 or 60, wherein the contacting the cell with an effective amount of the nucleic acid cassette of any one of claims 1-51, or the vector of any one of claims 52-58, results in at least a 5% reduction in UBE3A-ATS in the cell compared to a comparable untreated cell.

62. The method of any of claims 59-61, wherein the contacting the cell with an effective amount of the nucleic acid cassette of any one of claims 1-51, or the vector of any one of claims 52-58, results in at least a 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90% or 95% reduction in UBE3A-ATS in the cell compared to a comparable untreated cell.

63. The method of any of claims 59-62, wherein reduction in UBE3-ATS is measured by quantitative polymerase chain reaction.

64. An in vivo or in vitro method for inducing ubiquitin-protein ligase E3A (UBE3A) expression in a cell where UBE3A-ATS is expressed, the method comprising administering an effective amount of a nucleic acid cassette of any one of claims 1-51, or the vector of any one of claims 52-58, to the cell.

65. The method of claim 64, wherein expression of UBE3A in the cell is increased compared to a comparable cell not treated with the nucleic acid cassette of any one of claims 1-51, or the vector of any one of claims 52-58.

66. The method of claim 64 or 65, wherein expression of UBE3A in the cell is increased by at least 1.5 fold, 2, fold, 3 fold, or more than 3 fold compared to a comparable untreated cell.

67. The method of any of claims 64-66, wherein expression of paternal UBE3A in the cell is increased compared to a comparable cell not treated with the nucleic acid cassette of any one of claims 1-51, or the vector of any one of claims 52-58.

68. The method of claim 67, wherein expression of paternal UBE3A in the cell is increased by at least 1.5 fold, 2, fold, 3 fold, 4 fold, 6 fold, 7 fold, 8 fold, 9 fold, 10 fold, or more than 10 fold compared to a comparable untreated cell.

69. The method of any one of claims 59-68, wherein the cell is a cultured cell.

70. The method of claim 69, wherein the cell is a primary neuron, an IPSC derived neural cell, a neuronal cell line, an engineered cell line or a neural stem cell.

71. The method of any one of claims 59-68, wherein the cell is in vivo.

72. The method of claim 71, wherein the cell is a neuron.

73. The method of claim 71, wherein the cell is a neuron in the central nervous system(CNS), or a cell in contact with cerebral spinal fluid.

74. The method of any one of claims 59-73, wherein contacting the cell comprises delivering the nucleic acid cassette to the CNS or cerebral spinal fluid (CSF).

75. The method of any one of claims 59-74, wherein contacting the cell comprises delivering the nucleic acid cassette by intraparcnchymal injection, intrathecal injection, intra-cistcma magna injection, or intracerebroventricular injection.

76. A method for treating or preventing a neurological condition or disorder in a subject comprising administering a therapeutically or prophylactically effective amount of a pharmaceutical composition comprising a nucleic acid cassette of any one of claims 1-51, or the vector of any one of claims 52-58.

77. The method of claim 76, wherein the neurological condition or disorder is Angelman syndrome.

78. The method of claim 76, wherein the method comprises administering the pharmaceutical composition to the subject via intraparcnchymal injection, intrathecal injection, intra-cisterna magna injection, intravenous injection, or intracerebroventricular injection.

79. A use of the nucleic acid cassette of any one of claims 1-51, or the vector of any one of claims 52-58, in the manufacture of a medicament for the treatment of a neurological condition or disorder.

80. A method of inducing expression of paternal UBE3A in a cell where expression of paternal UBE3A is suppressed, comprising administering to the cell an oligonucleotide that is at least 90% complementary to a 10-30 nucleotide sequence of an mRNA expressed from a region between positions 25,170,426 and 25,252,333 on human chromosome 15.

81. The method of claim 80, wherein the oligonucleotide comprises an RNA backbone, a DNA backbone, a modified backbone, or a combination of one of more backbones.

82. A method of inducing expression of paternal UBE3A in a cell where expression of paternal UBE3A is suppressed, comprising administering to the cell an oligonucleotide of at least 90% complementary to a 10-30 nucleotide sequence between positions 25,170,426 and 25,252,333 on human chromosome 15, a shRNA comprising a sequence at least 90% complementary to a 10-30 nucleotide sequence between positions 25,170,426 and 25,252,333 on human chromosome 15, or a nucleic acid capable of expressing an RNA comprising a sequenceat least 90% complementary to a 10-30 nucleotide sequence between positions 25, 170,426 and 25,252,333 on human chromosome 15.

83. A method of inducing expression of paternal UBE3A in a cell where expression of paternal UBE3A is suppressed, comprising administering to the cell an oligonucleotide of SEQ ID Nos: 9-38, a shRNA comprising a sequence of SEQ ID Nos: 9-38, or a nucleic acid capable of expressing an RNA comprising a sequence of SEQ ID NO.: 9-38.

Citation Information

Patent Citations

  • Modulation of UBE3a-ATS expression

    US20150191723A1

  • shRNA TARGETING SNORD115 LOCATIONS TO RESTORE PATERNAL UBE3A GENE EXPRESSION IN ANGELMAN SYNDROME

    US20230332150A1

Cited By

  • Methods and compositions for increasing expression of UBE3a

    WO2025213123A1